WO2024009373A1 - Composition, method for selecting components in composition, method for producing composition, information processing system, and information processing method - Google Patents
Composition, method for selecting components in composition, method for producing composition, information processing system, and information processing method Download PDFInfo
- Publication number
- WO2024009373A1 WO2024009373A1 PCT/JP2022/026659 JP2022026659W WO2024009373A1 WO 2024009373 A1 WO2024009373 A1 WO 2024009373A1 JP 2022026659 W JP2022026659 W JP 2022026659W WO 2024009373 A1 WO2024009373 A1 WO 2024009373A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- intestinal environment
- effect
- expected
- component
- coverage rate
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 78
- 238000000034 method Methods 0.000 title claims description 36
- 230000010365 information processing Effects 0.000 title claims description 18
- 238000004519 manufacturing process Methods 0.000 title claims description 16
- 238000003672 processing method Methods 0.000 title claims description 6
- 230000000694 effects Effects 0.000 claims abstract description 130
- 230000000968 intestinal effect Effects 0.000 claims description 162
- 239000004615 ingredient Substances 0.000 claims description 28
- 238000004364 calculation method Methods 0.000 claims description 11
- 238000010187 selection method Methods 0.000 claims description 2
- 238000003860 storage Methods 0.000 description 40
- 241000894006 Bacteria Species 0.000 description 32
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 30
- 239000000126 substance Substances 0.000 description 30
- 235000013305 food Nutrition 0.000 description 25
- 235000013618 yogurt Nutrition 0.000 description 20
- 235000014655 lactic acid Nutrition 0.000 description 15
- 239000004310 lactic acid Substances 0.000 description 15
- 239000003814 drug Substances 0.000 description 12
- 239000013589 supplement Substances 0.000 description 11
- 230000035945 sensitivity Effects 0.000 description 10
- 229940079593 drug Drugs 0.000 description 7
- 239000002207 metabolite Substances 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 238000010586 diagram Methods 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 241000605861 Prevotella Species 0.000 description 5
- 230000002503 metabolic effect Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 235000013325 dietary fiber Nutrition 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 241000186000 Bifidobacterium Species 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 240000005979 Hordeum vulgare Species 0.000 description 2
- 235000007340 Hordeum vulgare Nutrition 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 102000038379 digestive enzymes Human genes 0.000 description 2
- 108091007734 digestive enzymes Proteins 0.000 description 2
- 230000002550 fecal effect Effects 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 239000010794 food waste Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 241000203069 Archaea Species 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000257303 Hymenoptera Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 1
- 244000017020 Ipomoea batatas Species 0.000 description 1
- 235000002678 Ipomoea batatas Nutrition 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 238000003066 decision tree Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 235000021107 fermented food Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 238000013332 literature search Methods 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 238000010801 machine learning Methods 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000010295 mobile communication Methods 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 235000013557 nattō Nutrition 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 235000021110 pickles Nutrition 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000007637 random forest analysis Methods 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to a composition, a method for selecting components in the composition, a method for producing the composition, an information processing system, and an information processing method.
- compositions such as foods and supplements that have functionality are known (hereinafter also referred to as "functional substances").
- functional substances for example, in order to provide yogurt that is effective in maintaining eye health in addition to improving the intestinal environment, there is a method for producing yogurt containing sugarcane dietary fiber and sweet potato stems and leaves (for example, Patent Document 1 etc).
- An object of the present invention is to provide a composition that has a high coverage rate for a predetermined effect in a predetermined population.
- the main invention of the present invention for solving the above problems is as follows: A composition containing two or more components having a predetermined effect,
- the composition is a composition in which each of the components is selected such that the total coverage rate, which indicates the proportion of subjects for whom the above effect can be expected, is equal to or higher than a predetermined proportion in a predetermined group.
- composition that has a high coverage rate for a predetermined effect in a predetermined population.
- FIG. 1 is a diagram illustrating a configuration example of an information processing system.
- [Item 3] Contains a first component and a second component that are expected to have the first effect,
- the first component has a coverage rate X of a first intestinal environment pattern in which the first effect can be expected
- the second component has a coverage rate Y of a second intestinal environment pattern in which the first effect can be expected
- a composition in which the total coverage of the first and second intestinal environment patterns is equal to or higher than a predetermined ratio.
- [Item 4] obtaining a first intestinal environment pattern in which the first effect can be expected for the first ingredient; calculating the coverage rate of the first intestinal environment pattern; determining whether the coverage rate is equal to or higher than a reference value; searching for a second component that is expected to have the first effect on a second intestinal environment pattern; In the second component, acquiring the second intestinal environment pattern; calculating the coverage of the first and second intestinal environment patterns; producing a composition containing the first and second components; A composition obtained by.
- a method for selecting components in a composition containing two or more components having a predetermined effect comprising: A selection method in which each of the components is selected such that a total coverage rate indicating the proportion of subjects for whom the effect can be expected in a predetermined group is equal to or higher than a predetermined proportion.
- a method for selecting components in a composition containing two or more components having a predetermined effect comprising: The ingredients are selected such that the total coverage rate indicating the proportion of subjects with the intestinal environment pattern in which the effect set for each ingredient can be expected in a predetermined population is equal to or higher than a predetermined proportion.
- [Item 7] Contains a first component and a second component that are expected to have the first effect,
- the first component has a coverage rate X of a first intestinal environment pattern in which the first effect can be expected
- the second component has a coverage rate Y of a second intestinal environment pattern in which the first effect can be expected
- a method for selecting components in a composition wherein the total coverage of the first and second intestinal environment patterns is equal to or higher than a predetermined ratio.
- [Item 8] obtaining a first intestinal environment pattern in which the first effect can be expected for the first ingredient; calculating the coverage rate of the first intestinal environment pattern; determining whether the coverage rate is equal to or higher than a reference value; searching for a second component that is expected to have the first effect on a second intestinal environment pattern; In the second component, acquiring the second intestinal environment pattern; calculating the coverage of the first and second intestinal environment patterns; producing a composition containing the first and second components; A method for selecting components in a composition obtained by [Item 9] A method for producing a composition containing two or more components having a predetermined effect, the method comprising: A method for producing a composition, wherein each of the components is selected such that the total coverage rate, which indicates the proportion of subjects for whom the effect can be expected in a predetermined group, is equal to or higher than a predetermined proportion.
- a method for producing a composition containing two or more components having a predetermined effect comprising: A composition in which the ingredients are selected such that the total coverage rate indicating the proportion of subjects with the intestinal environment pattern in which the effect set for each ingredient can be expected in a predetermined population is equal to or higher than a predetermined proportion. How things are manufactured.
- [Item 11] Contains a first component and a second component that are expected to have the first effect,
- the first component has a coverage rate X of a first intestinal environment pattern in which the first effect can be expected
- the second component has a coverage rate Y of a second intestinal environment pattern in which the first effect can be expected
- a method for producing a composition wherein the total coverage of the first and second intestinal environment patterns is equal to or higher than a predetermined ratio.
- [Item 12] obtaining a first intestinal environment pattern in which the first effect can be expected for the first ingredient; calculating the coverage rate of the first intestinal environment pattern; determining whether the coverage rate is equal to or higher than a reference value; searching for a second component that is expected to have the first effect on a second intestinal environment pattern; In the second component, acquiring the second intestinal environment pattern; calculating the coverage of the first and second intestinal environment patterns; producing a composition containing the first and second components;
- An information processing method using a computer comprising:
- an estimated value indicating the proportion of subjects who can expect a predetermined effect by ingesting a predetermined ingredient can be defined as a coverage rate (occupancy rate).
- Specified groups include, for example, race (Asian, European, etc.), nationality (Japanese, Chinese, etc.), gender (male, female, etc.), age (infants, toddlers, elementary school students, elderly, etc.), etc.
- the group can be set by Further, groups such as residents of a predetermined nursing home, children of a predetermined elementary school, children of a predetermined nursery school, a predetermined family, a predetermined sports team, and employees of a predetermined company can be set arbitrarily. Or, if you are a group of people with specific physical conditions or thoughts, such as those with a tendency to constipation, high uric acid levels, poor sleep, wanting to prevent diseases, or taking prescribed medicines. Good too. Furthermore, the group may be set by a combination of these.
- the present invention provides a functional substance that has a high coverage rate for a predetermined effect in a predetermined population by selecting components and designing a composition using a new method.
- the investigation method for finding a responsive intestinal environment pattern can be carried out by a known method, and for example, it can be carried out by the following method.
- a composition means one containing multiple components.
- Examples of the form of the composition according to the present embodiment include forms such as pharmaceuticals, food additives, supplements, and foods.
- the dosage forms include solid forms such as powders, tablets, sugar-coated agents, capsules, granules, dry syrups, liquids, syrups, drops, and drinks.
- a liquid dosage form can be mentioned.
- composition according to the embodiments below is a food
- it can be in the form of ordinary food and drink such as confectionery, drinks, yogurt, processed foods, health foods, and infant foods.
- it When it is in the form of a food or drink, it can be manufactured by adding active ingredients in a normal manufacturing process.
- the amount of intake can be any amount and any period of intake.
- the intake or administration amount can be, for example, 0.015 g/kg or more per day.
- the intake amount is not limited to once a day, but may be divided into multiple doses.
- the amount of intake can be any amount and any period of intake.
- the predetermined component can be lactic acid bacteria
- the predetermined effect includes improving bowel movements.
- non-responders intestinal environment type B
- yogurt produced by lactic acid bacteria X are responders to lactic acid bacteria Y, so by making yogurt containing lactic acid bacteria X and lactic acid bacteria Y, Both people with intestinal environment type A and people with intestinal environment type B become responders to the yogurt, and as a result, the coverage rate of the yogurt increases.
- non-responders to yogurt produced by lactic acid bacteria X can be made into responders by adding a material other than lactic acid bacteria X, thereby increasing the coverage of the yogurt. .
- the components other than lactic acid bacteria to obtain the effect of improving bowel movements may be, for example, dietary fiber or oligosaccharides, or other substances such as vitamins or minerals.
- intestinal environment pattern refers to the presence or absence of specific intestinal bacteria, relative abundance ratio, balance among intestinal bacteria, presence or absence of intestinal metabolites, content, balance among metabolites, stool Presence and content of intermediate proteins (including but not limited to digestive enzymes, antibacterial peptides, hormonal substances, etc.), presence and content of immune-related substances such as IgA, stool properties (e.g. water content, hardness, color) etc.) and combinations thereof.
- the intestinal bacteria are not limited to bacteria, but include archaea, fungi, and viruses (phages).
- the intestinal metabolic substances include metabolic substances produced by intestinal bacteria, dead intestinal bacteria, food residue, substances secreted by the host, etc., and are mainly detected in stool.
- fecal proteins include proteins produced by intestinal bacteria, food residues, and substances secreted by the host (digestive enzymes, immunoglobulins, antibacterial peptides, etc.), and are mainly detected in feces. It may also be detected from contents other than stool.
- the term "functional substance” as used herein refers to food (including beverages; the same applies hereinafter) that is expected to have a predetermined effect when ingested; , including cases where the food is a food with functional claims, a food for specified health uses, or a food for special purposes.
- “functional substances” include medicines, supplements, etc.
- food includes ingredients and specific nutrients contained in ingredients.
- “medicinal products” and “supplements” may refer to active ingredients (compounds) contained therein.
- the prescribed effects of functional substances include, for example, weight loss, resistance to gaining weight, lowering blood sugar levels, improving glucose tolerance, improving bowel movements, improving immunity, alleviating atopic dermatitis and allergies, etc.
- the person taking the functional substance in this embodiment is not limited to humans, but can also be applied to animals such as livestock and pets, or industrial animals such as bees and silkworms.
- An information processing system provides a user terminal with information for producing a composition that has a high coverage rate for a predetermined effect in a predetermined group, for example.
- the system according to this embodiment includes a server 1.
- a user terminal 2 is connected to the server 1 via a network such as the Internet. Although one user terminal 2 is illustrated in FIG. 1 for convenience of explanation, a plurality of terminals can be connected to the network of this system.
- the server 1 and the user terminal 2 have the following hardware configurations. Note that the following configuration is an example, and other configurations may be used.
- FIG. 2 is a diagram showing the hardware configuration of the server 1.
- the server 1 may be, for example, a general-purpose computer such as a workstation or a personal computer, or may be logically realized by cloud computing.
- the server 1 includes at least a processor 10, a memory 11, a storage 12, a transmitting/receiving section 13, an input/output section 14, etc., which are electrically connected to each other via a bus 15.
- the processor 10 is an arithmetic device that controls the overall operation of the server 1, controls the transmission and reception of data between each element, and performs information processing necessary for executing applications.
- the processor 10 is a CPU (Central Processing Unit), and executes programs stored in the storage 12 and developed in the memory 11 to perform various information processing.
- CPU Central Processing Unit
- the memory 11 includes a main memory configured with a volatile storage device such as a DRAM (Dynamic Random Access Memory), and an auxiliary memory configured with a non-volatile storage device such as a flash memory or an HDD (Hard Disc Drive). .
- the memory 11 is used as a work area for the processor 10, and also stores a BIOS (Basic Input/Output System) executed when the server 1 is started, various setting information, and the like.
- BIOS Basic Input/Output System
- the storage 12 stores various programs such as application programs.
- a database storing data used for each process may be constructed in the storage 12.
- the transmitting/receiving unit 13 connects the server 1 to the network 3.
- the transmitting/receiving unit 13 may include a short-range communication interface of Bluetooth (registered trademark) and BLE (Bluetooth Low Energy).
- the input/output unit 14 is information input devices such as a keyboard and mouse, and output devices such as a display, which are used as necessary.
- the bus 15 is commonly connected to each of the above elements and transmits, for example, address signals, data signals, and various control signals.
- the user terminal 2 executes information processing through communication with the server 1.
- the user terminal 2 can be, for example, a terminal for controlling a system for manufacturing a composition.
- the user terminal 2 may be, for example, a general-purpose computer such as a workstation or a personal computer, or a mobile communication device such as a smartphone.
- FIG. 3 is a diagram showing an example of the software configuration of the server 1 in the system of the present invention.
- the server 1 includes an acquisition section 111, a calculation section 112, a judgment section 113, a search section 114, an information provision section 115, a responsive intestinal environment information storage section 121, a coverage storage section 122, an acquired information storage section 123, and an additional information storage section. 124.
- the acquisition unit 111, the calculation unit 112, the determination unit 113, the search unit 114, and the information provision unit 115 are realized by the processor 10 included in the server reading a program stored in the storage 12 into the memory 11 and executing it.
- the responsive intestinal environment information storage unit 121, the coverage storage unit 122, the acquired information storage unit 123, and the additional information storage unit 124 are realized as part of the storage area provided by at least one of the memory 11 and the storage 12. be done.
- the responsive intestinal environment information storage unit 121 includes a combination of a specific functional substance and a characteristic of a responsive intestinal environment pattern that can obtain the effects of the functional substance.
- a characteristic of a responsive intestinal environment pattern that can obtain the effects of the functional substance.
- FIG. 4 is a configuration example of the responsive intestinal environment information stored in the responsive intestinal environment information storage unit 121.
- Responsive intestinal environment information is linked to the ID assigned to each functional substance, and includes information on the category of the functional substance (foods, supplements, medicines, etc.), and the effects obtained by ingesting the functional substance (relieves constipation). weight loss, improved glucose tolerance, etc.) and responsive intestinal environment pattern information.
- Responsive intestinal environment pattern information includes the presence, abundance, and relative abundance ratio of specific intestinal bacteria, the balance among intestinal bacteria (existence ratio of specific intestinal bacteria, etc.), and the presence or absence of intestinal metabolites. , content, balance between metabolites, presence or absence of protein in stool, content, stool properties (for example, water content, hardness, color, etc.).
- the specific method used for intestinal bacteria such as its genus (such as Prevotella bacteria) and species (such as Prevotella copuli), does not matter.
- the range for determining a responder can be defined by numerical values (threshold values).
- the threshold value is a cutoff value for distinguishing between a group that is effective and a group that is not effective when ingesting the functional substance, and can be determined as appropriate.
- the cutoff value may be calculated by appropriately selecting a machine learning algorithm such as a decision tree, random forest, or logistic regression, or may be determined as appropriate from the distribution of values of the effective group and the non-effective group. More specifically, for example, the relationship between sensitivity and false positive rate (1-specificity) can be determined by ROC analysis.
- Sensitivity is, for example, the rate at which a prediction target, which is a group whose true state increases, is correctly predicted to be a group whose true state increases. Specificity is the rate at which a prediction target whose true state is a group that does not increase is correctly predicted to be a group that does not increase.
- the values of sensitivity and false positive rate are determined when the cutoff value is continuously changed. Then, plot the obtained sensitivity and false positive rate values on a graph where the vertical axis (Y axis) is the sensitivity and the horizontal axis (X axis) is the false positive rate, and from among the plotted points, the sensitivity 1.
- the cutoff value corresponding to the combination of sensitivity and specificity determined in this way can be set as the final cutoff value.
- the method for determining the combination of sensitivity and specificity is not limited to the method of determining the combination that minimizes (1-sensitivity) 2 + false positive rate 2 , for example, The combination may be determined to maximize the product of , or the combination may be determined to maximize (sensitivity + specificity) ⁇ 2.
- the acquired information storage unit 123 stores information acquired by the acquisition unit 111.
- the information stored in the acquired information storage unit 123 is provided to the user terminal 2 and the like by the information providing unit 115.
- the acquired information includes, for example, a predetermined effect in a predetermined group obtained by the obtaining unit 111 , information regarding the intestinal environment pattern in which the predetermined effect can be expected, a coverage rate calculated by the calculating unit 112 , and the determining unit 113 This is the information obtained by the search unit 114 as a result of the determination.
- the additional information storage unit 124 stores, for example, information added to the above-mentioned acquired information.
- the additional information can be, for example, information on other effects that each component has, where the component is obtained, a form suitable for a composition containing the component, and a manufacturing method thereof.
- the form is a food or a food ingredient, it can be a food containing the food or recipe information using the food. It may also include the frequency and amount of ingestion of the composition, and if the composition is a supplement or medicine, it may also include precautions for use such as the dosage and usage of the supplement or medicine.
- the acquisition unit 111 acquires intestinal environment patterns in which a predetermined effect can be expected in a plurality of components that the composition will contain. That is, data regarding a predetermined effect in a predetermined population and an intestinal environment pattern in which the predetermined effect can be expected is obtained.
- the acquisition unit 111 acquires the analyzed intestinal bacteria pattern information from the user terminal 2 or the server 1 (for example, the responsive intestinal environment information storage unit 121 or the coverage storage unit 122), or from another data server. You may. Alternatively, it may be obtained through a clinical trial.
- the calculation unit 112 calculates the coverage rate of the acquired intestinal environment pattern.
- the calculation unit 112 may calculate the coverage rate each time an intestinal environment pattern is acquired, or may acquire the coverage rate from a database such as the coverage storage unit 122.
- the calculation unit 112 transmits the calculated coverage rate to the determination unit 113.
- the determining unit 113 determines whether the calculated coverage rate is equal to or higher than a reference value (for example, 90%).
- the reference value can be set as appropriate.
- the determining unit 113 informs the information providing unit 115 whether the coverage rate is equal to or higher than the reference value.
- the search unit 114 searches for a component that can be expected to have a predetermined effect from the information stored in the coverage storage unit 122. For example, when there is an intestinal environment pattern X in which the effect a of component A can be expected, the search unit 114 searches for other components other than component A that can be expected to have the effect a in intestinal environment patterns other than the intestinal environment pattern X. .
- the information providing unit 115 provides the information acquired and stored in the acquired information storage unit 123 to the user terminal 2, for example.
- the acquired information includes, for example, a predetermined effect in a predetermined group obtained by the obtaining unit 111 , information regarding the intestinal environment pattern in which the predetermined effect can be expected, a coverage rate calculated by the calculating unit 112 , and the determining unit 113 This is the information obtained by the search unit 114 as a result of the determination.
- the above additional information may be added to each piece of information as necessary.
- FIG. 6 is a diagram showing the flow of processing for selecting components in a composition executed in the server 1.
- the acquisition unit 111 acquires an intestinal environment pattern X in which a component A having a predetermined effect a is considered to bring about an effect a (S101).
- the intestinal environment pattern X can be acquired from the responsive intestinal environment information stored in the responsive intestinal environment information storage unit 121, other databases, literature information, clinical test results, and the like.
- the calculation unit 112 calculates the coverage rate of the acquired intestinal environment pattern X (S102).
- the coverage rate may be calculated each time an intestinal environment pattern is acquired, or the coverage rate may be acquired from a database such as the coverage storage unit 122. Alternatively, at this time, information on a new predetermined group consisting of people (or animals, etc.) whose intestinal environment patterns are known may be given, and the intestinal environment pattern X+Y for the predetermined group may be given.
- a reference value for example, 90%
- the search unit 114 searches for other components that can be expected to have effect a from the information stored in the coverage storage unit 122 (S104).
- component B is found to be another component that can be expected to have effect a
- an intestinal environment pattern Y in which component B is thought to bring about effect a is acquired (S105). Similar to the intestinal environment pattern X, the intestinal environment pattern Y is obtained from the responsive intestinal environment information stored in the responsive intestinal environment information storage unit 121, other databases, literature information, clinical trial results, etc. can do.
- the calculation unit 112 calculates the coverage rate of the acquired intestinal environment pattern X+Y (S106).
- the coverage rate may be the sum of the coverage rate of intestinal environment pattern Alternatively, if there is an overlap between the intestinal environment pattern X and the intestinal environment pattern Y, the value may be a value that takes this into consideration.
- the coverage rate may be calculated in this step, or may be obtained from a database such as a coverage list stored in the coverage storage unit 122.
- the target population for calculating the coverage rate here is, in principle, the same as the target population in S102, but it is composed of people (or animals, etc.) whose intestinal environment patterns are known at this time. Information on a new predetermined group may be given, and the coverage rate of the intestinal environment pattern X+Y for the predetermined group may be calculated.
- the information providing unit 115 provides the information stored in the acquired information storage unit 123, for example, to the user terminal 2 (S108). The above additional information may be added to each piece of information as necessary. Then, based on the data provided to the user terminal 2, a composition containing a plurality of components having a predetermined effect a is manufactured (not shown).
- a composition containing a component having a predetermined effect is considered to have that effect on a subject who does not have that effect (i.e., a non-responder).
- Another component can be searched for through databases, literature searches, etc., and this other component can also be included.
- the present invention provides a functional substance that has a high coverage rate for a predetermined effect in a predetermined population using a new design method.
- the selection starts with component A having a predetermined effect a, and the selection is performed such that a predetermined coverage rate is satisfied and the number of components is minimized.
- the number of components can be appropriately selected so as to maximize the coverage and keep the number of components to a predetermined number or less.
- the components can be appropriately selected so as to maximize the coverage rate.
- the predetermined effect a is a bowel movement improving effect
- component A can be Bifidobacterium BB536
- component B can be LB81 lactic acid bacteria
- component C can be Lacris. It is preferable that the yogurt does not contain any other ingredients that would make the yogurt taste unpleasant (for example, "soy sauce” as an ingredient) for the purpose of improving bowel movements.
Abstract
[Problem] To provide a composition that has a high coverage ratio of a prescribed effect in a prescribed population. [Solution] A composition according to the present invention contains two or more components having a prescribed effect and allows each of the components to be selected such that the sum of coverage ratios that indicate the proportion of subjects in a prescribed population for which the effect can be expected is greater than or equal to a prescribed proportion.
Description
本発明は、組成物、組成物における成分の選択方法、組成物の製造方法、情報処理システムおよび情報処理方法
に関する。 The present invention relates to a composition, a method for selecting components in the composition, a method for producing the composition, an information processing system, and an information processing method.
に関する。 The present invention relates to a composition, a method for selecting components in the composition, a method for producing the composition, an information processing system, and an information processing method.
機能性を有する、食品やサプリメント等の組成物が知られている（以下、「機能性物質」とも呼ぶ。）。例えば、腸内環境改善効果に加えて、目の健康維持に効果のあるヨーグルトを提供するために、サトウキビの食物繊維および甘藷の茎葉を含有するヨーグルトを製造する方法がある（例えば、特許文献１等）。
Compositions such as foods and supplements that have functionality are known (hereinafter also referred to as "functional substances"). For example, in order to provide yogurt that is effective in maintaining eye health in addition to improving the intestinal environment, there is a method for producing yogurt containing sugarcane dietary fiber and sweet potato stems and leaves (for example, Patent Document 1 etc).
複数の成分を含有することにより、このような機能性を有する組成物は摂取した対象者に対する所定の効果を高めるものである。一方で、所定の集団において、その組成物を摂取することで所定の効果が期待できる対象者の割合を示すカバー率が高くなるような組成物も望まれる。
By containing a plurality of components, a composition having such functionality enhances a predetermined effect on the subject who ingests it. On the other hand, it is also desirable to have a composition that has a high coverage rate, which indicates the proportion of subjects in a given group who can expect a certain effect by ingesting the composition.
本発明は、所定の集団において、所定の効果に対するカバー率が高い組成物を提供することを目的とする。
An object of the present invention is to provide a composition that has a high coverage rate for a predetermined effect in a predetermined population.
上記課題を解決するための本発明の主たる発明は、
所定の効果を有する２つ以上の成分を含有する組成物であって、
前記各成分が、所定の集団において、前記効果が期待できる対象者の割合を示すカバー率の合計が所定の割合以上になるように選択された、組成物である。 The main invention of the present invention for solving the above problems is as follows:
A composition containing two or more components having a predetermined effect,
The composition is a composition in which each of the components is selected such that the total coverage rate, which indicates the proportion of subjects for whom the above effect can be expected, is equal to or higher than a predetermined proportion in a predetermined group.
所定の効果を有する２つ以上の成分を含有する組成物であって、
前記各成分が、所定の集団において、前記効果が期待できる対象者の割合を示すカバー率の合計が所定の割合以上になるように選択された、組成物である。 The main invention of the present invention for solving the above problems is as follows:
A composition containing two or more components having a predetermined effect,
The composition is a composition in which each of the components is selected such that the total coverage rate, which indicates the proportion of subjects for whom the above effect can be expected, is equal to or higher than a predetermined proportion in a predetermined group.
その他、本願が開示する課題やその解決方法については、発明の実施形態の欄及び図面により明らかにされる。
Other problems and solutions disclosed in the present application will be made clear by the embodiments section and the drawings.
本発明によれば、所定の集団において、所定の効果に対するカバー率が高い組成物を提供することができる。
According to the present invention, it is possible to provide a composition that has a high coverage rate for a predetermined effect in a predetermined population.
以下に、組成物、情報処理システムおよび情報処理方法の実施形態を、図面に基づいて説明する。なお、本実施形態により本発明が限定されるものではない。
Below, embodiments of a composition, an information processing system, and an information processing method will be described based on the drawings. Note that the present invention is not limited to this embodiment.
本発明は、例えば、以下のような構成を備える。
［項目１］
所定の効果を有する２つ以上の成分を含有する組成物であって、
前記各成分が、所定の集団において、前記効果が期待できる対象者の割合を示すカバー率の合計が所定の割合以上になるように選択された、組成物。
［項目２］
所定の効果を有する２つ以上の成分を含有する組成物であって、
前記成分が、所定の集団において、前記各成分について設定された前記効果が期待できる腸内環境パターンの対象者の割合を示すカバー率の合計が所定の割合以上になるように選択された、組成物。
［項目３］
第１の効果が見込める第１の成分および第２の成分を含有し、
前記第１の成分は、前記第１の効果が見込める第１の腸内環境パターンのカバー率Ｘを有し、
前記第２の成分は、前記第１の効果が見込める第２の腸内環境パターンのカバー率Ｙを有し、
前記第１および第２の腸内環境パターンのカバー率の合計が所定の割合以上である、組成物。
［項目４］
第１の成分において、第１の効果が見込める第１の腸内環境パターンを取得するステップと、
前記第１の腸内環境パターンのカバー率を算出するステップと、
前記カバー率が基準値以上であるかを判断するするステップと、
第２の腸内環境パターンに前記第１の効果が見込める第２の成分を探索するステップと、
前記第２の成分において、前記第２の腸内環境パターンを取得するステップと、
前記第１および第２の腸内環境パターンのカバー率を算出するステップと、
前記第１および第２の成分を含有する組成物を製造するステップと、
により得られた、組成物。
［項目５］
所定の効果を有する２つ以上の成分を含有する、組成物における成分の選択方法であって、
前記各成分が、所定の集団において、前記効果が期待できる対象者の割合を示すカバー率の合計が所定の割合以上になるように選択された、選択方法。
［項目６］
所定の効果を有する２つ以上の成分を含有する、組成物における成分の選択方法であって、
前記成分が、所定の集団において、前記各成分について設定された前記効果が期待できる腸内環境パターンの対象者の割合を示すカバー率の合計が所定の割合以上になるように選択された、選択方法。
［項目７］
第１の効果が見込める第１の成分および第２の成分を含有し、
前記第１の成分は、前記第１の効果が見込める第１の腸内環境パターンのカバー率Ｘを有し、
前記第２の成分は、前記第１の効果が見込める第２の腸内環境パターンのカバー率Ｙを有し、
前記第１および第２の腸内環境パターンのカバー率の合計が所定の割合以上である、組成物における成分の選択方法。
［項目８］
第１の成分において、第１の効果が見込める第１の腸内環境パターンを取得するステップと、
前記第１の腸内環境パターンのカバー率を算出するステップと、
前記カバー率が基準値以上であるかを判断するするステップと、
第２の腸内環境パターンに前記第１の効果が見込める第２の成分を探索するステップと、
前記第２の成分において、前記第２の腸内環境パターンを取得するステップと、
前記第１および第２の腸内環境パターンのカバー率を算出するステップと、
前記第１および第２の成分を含有する組成物を製造するステップと、
により得られた、組成物における成分の選択方法。
［項目９］
所定の効果を有する２つ以上の成分を含有する、組成物の製造方法であって、
前記各成分が、所定の集団において、前記効果が期待できる対象者の割合を示すカバー率の合計が所定の割合以上になるように選択された、組成物の製造方法。
［項目１０］
所定の効果を有する２つ以上の成分を含有する、組成物の製造方法であって、
前記成分が、所定の集団において、前記各成分について設定された前記効果が期待できる腸内環境パターンの対象者の割合を示すカバー率の合計が所定の割合以上になるように選択された、組成物の製造方法。
［項目１１］
第１の効果が見込める第１の成分および第２の成分を含有し、
前記第１の成分は、前記第１の効果が見込める第１の腸内環境パターンのカバー率Ｘを有し、
前記第２の成分は、前記第１の効果が見込める第２の腸内環境パターンのカバー率Ｙを有し、
前記第１および第２の腸内環境パターンのカバー率の合計が所定の割合以上である、組成物の製造方法。
［項目１２］
第１の成分において、第１の効果が見込める第１の腸内環境パターンを取得するステップと、
前記第１の腸内環境パターンのカバー率を算出するステップと、
前記カバー率が基準値以上であるかを判断するするステップと、
第２の腸内環境パターンに前記第１の効果が見込める第２の成分を探索するステップと、
前記第２の成分において、前記第２の腸内環境パターンを取得するステップと、
前記第１および第２の腸内環境パターンのカバー率を算出するステップと、
前記第１および第２の成分を含有する組成物を製造するステップと、
により得られた、組成物の製造方法。
［項目１３］
第１の成分において、第１の効果が見込める第１の腸内環境パターンを取得する取得部と、
前記第１の腸内環境パターンのカバー率を算出する算出部と、
前記カバー率が基準値以上であるかを判断するする判断部と、
第２の腸内環境パターンに前記第１の効果が見込める第２の成分を探索する探索部と、
取得された情報を提供する情報提供部と、を備え、
前記取得部は、前記第２の成分において、前記第２の腸内環境パターンを取得し、
前記算出部は、前記第１および第２の腸内環境パターンのカバー率を算出する、情報処理システム。
［項目１４］
第１の成分において、第１の効果が見込める第１の腸内環境パターンを取得するステップと、
前記第１の腸内環境パターンのカバー率を算出するステップと、
前記カバー率が基準値以上であるかを判断するするステップと、
第２の腸内環境パターンに前記第１の効果が見込める第２の成分を探索するステップと、
前記第２の成分において、前記第２の腸内環境パターンを取得するステップと、
前記第１および第２の腸内環境パターンのカバー率を算出するステップと、
取得された情報を提供するステップと、
を有する、コンピュータによる情報処理方法。 The present invention includes, for example, the following configuration.
[Item 1]
A composition containing two or more components having a predetermined effect,
A composition in which each of the components is selected such that the total coverage rate, which indicates the proportion of subjects for whom the effect can be expected in a predetermined group, is equal to or higher than a predetermined proportion.
[Item 2]
A composition containing two or more components having a predetermined effect,
A composition in which the ingredients are selected such that the total coverage rate indicating the proportion of subjects with the intestinal environment pattern in which the effect set for each ingredient can be expected in a predetermined population is equal to or higher than a predetermined proportion. thing.
[Item 3]
Contains a first component and a second component that are expected to have the first effect,
The first component has a coverage rate X of a first intestinal environment pattern in which the first effect can be expected,
The second component has a coverage rate Y of a second intestinal environment pattern in which the first effect can be expected,
A composition in which the total coverage of the first and second intestinal environment patterns is equal to or higher than a predetermined ratio.
[Item 4]
obtaining a first intestinal environment pattern in which the first effect can be expected for the first ingredient;
calculating the coverage rate of the first intestinal environment pattern;
determining whether the coverage rate is equal to or higher than a reference value;
searching for a second component that is expected to have the first effect on a second intestinal environment pattern;
In the second component, acquiring the second intestinal environment pattern;
calculating the coverage of the first and second intestinal environment patterns;
producing a composition containing the first and second components;
A composition obtained by.
[Item 5]
A method for selecting components in a composition containing two or more components having a predetermined effect, the method comprising:
A selection method in which each of the components is selected such that a total coverage rate indicating the proportion of subjects for whom the effect can be expected in a predetermined group is equal to or higher than a predetermined proportion.
[Item 6]
A method for selecting components in a composition containing two or more components having a predetermined effect, the method comprising:
The ingredients are selected such that the total coverage rate indicating the proportion of subjects with the intestinal environment pattern in which the effect set for each ingredient can be expected in a predetermined population is equal to or higher than a predetermined proportion. Method.
[Item 7]
Contains a first component and a second component that are expected to have the first effect,
The first component has a coverage rate X of a first intestinal environment pattern in which the first effect can be expected,
The second component has a coverage rate Y of a second intestinal environment pattern in which the first effect can be expected,
A method for selecting components in a composition, wherein the total coverage of the first and second intestinal environment patterns is equal to or higher than a predetermined ratio.
[Item 8]
obtaining a first intestinal environment pattern in which the first effect can be expected for the first ingredient;
calculating the coverage rate of the first intestinal environment pattern;
determining whether the coverage rate is equal to or higher than a reference value;
searching for a second component that is expected to have the first effect on a second intestinal environment pattern;
In the second component, acquiring the second intestinal environment pattern;
calculating the coverage of the first and second intestinal environment patterns;
producing a composition containing the first and second components;
A method for selecting components in a composition obtained by
[Item 9]
A method for producing a composition containing two or more components having a predetermined effect, the method comprising:
A method for producing a composition, wherein each of the components is selected such that the total coverage rate, which indicates the proportion of subjects for whom the effect can be expected in a predetermined group, is equal to or higher than a predetermined proportion.
[Item 10]
A method for producing a composition containing two or more components having a predetermined effect, the method comprising:
A composition in which the ingredients are selected such that the total coverage rate indicating the proportion of subjects with the intestinal environment pattern in which the effect set for each ingredient can be expected in a predetermined population is equal to or higher than a predetermined proportion. How things are manufactured.
[Item 11]
Contains a first component and a second component that are expected to have the first effect,
The first component has a coverage rate X of a first intestinal environment pattern in which the first effect can be expected,
The second component has a coverage rate Y of a second intestinal environment pattern in which the first effect can be expected,
A method for producing a composition, wherein the total coverage of the first and second intestinal environment patterns is equal to or higher than a predetermined ratio.
[Item 12]
obtaining a first intestinal environment pattern in which the first effect can be expected for the first ingredient;
calculating the coverage rate of the first intestinal environment pattern;
determining whether the coverage rate is equal to or higher than a reference value;
searching for a second component that is expected to have the first effect on a second intestinal environment pattern;
In the second component, acquiring the second intestinal environment pattern;
calculating the coverage of the first and second intestinal environment patterns;
producing a composition containing the first and second components;
A method for producing a composition obtained by
[Item 13]
an acquisition unit that acquires a first intestinal environment pattern in which a first effect can be expected for the first component;
a calculation unit that calculates the coverage rate of the first intestinal environment pattern;
a determination unit that determines whether the coverage rate is equal to or higher than a reference value;
a search unit that searches for a second component that is expected to have the first effect on a second intestinal environment pattern;
an information provision unit that provides the acquired information;
The acquisition unit acquires the second intestinal environment pattern in the second component,
The information processing system, wherein the calculation unit calculates coverage rates of the first and second intestinal environment patterns.
[Item 14]
obtaining a first intestinal environment pattern in which the first effect can be expected for the first ingredient;
calculating the coverage rate of the first intestinal environment pattern;
determining whether the coverage rate is equal to or higher than a reference value;
searching for a second component that is expected to have the first effect on a second intestinal environment pattern;
In the second component, acquiring the second intestinal environment pattern;
calculating the coverage of the first and second intestinal environment patterns;
providing the obtained information;
An information processing method using a computer, comprising:
［項目１］
所定の効果を有する２つ以上の成分を含有する組成物であって、
前記各成分が、所定の集団において、前記効果が期待できる対象者の割合を示すカバー率の合計が所定の割合以上になるように選択された、組成物。
［項目２］
所定の効果を有する２つ以上の成分を含有する組成物であって、
前記成分が、所定の集団において、前記各成分について設定された前記効果が期待できる腸内環境パターンの対象者の割合を示すカバー率の合計が所定の割合以上になるように選択された、組成物。
［項目３］
第１の効果が見込める第１の成分および第２の成分を含有し、
前記第１の成分は、前記第１の効果が見込める第１の腸内環境パターンのカバー率Ｘを有し、
前記第２の成分は、前記第１の効果が見込める第２の腸内環境パターンのカバー率Ｙを有し、
前記第１および第２の腸内環境パターンのカバー率の合計が所定の割合以上である、組成物。
［項目４］
第１の成分において、第１の効果が見込める第１の腸内環境パターンを取得するステップと、
前記第１の腸内環境パターンのカバー率を算出するステップと、
前記カバー率が基準値以上であるかを判断するするステップと、
第２の腸内環境パターンに前記第１の効果が見込める第２の成分を探索するステップと、
前記第２の成分において、前記第２の腸内環境パターンを取得するステップと、
前記第１および第２の腸内環境パターンのカバー率を算出するステップと、
前記第１および第２の成分を含有する組成物を製造するステップと、
により得られた、組成物。
［項目５］
所定の効果を有する２つ以上の成分を含有する、組成物における成分の選択方法であって、
前記各成分が、所定の集団において、前記効果が期待できる対象者の割合を示すカバー率の合計が所定の割合以上になるように選択された、選択方法。
［項目６］
所定の効果を有する２つ以上の成分を含有する、組成物における成分の選択方法であって、
前記成分が、所定の集団において、前記各成分について設定された前記効果が期待できる腸内環境パターンの対象者の割合を示すカバー率の合計が所定の割合以上になるように選択された、選択方法。
［項目７］
第１の効果が見込める第１の成分および第２の成分を含有し、
前記第１の成分は、前記第１の効果が見込める第１の腸内環境パターンのカバー率Ｘを有し、
前記第２の成分は、前記第１の効果が見込める第２の腸内環境パターンのカバー率Ｙを有し、
前記第１および第２の腸内環境パターンのカバー率の合計が所定の割合以上である、組成物における成分の選択方法。
［項目８］
第１の成分において、第１の効果が見込める第１の腸内環境パターンを取得するステップと、
前記第１の腸内環境パターンのカバー率を算出するステップと、
前記カバー率が基準値以上であるかを判断するするステップと、
第２の腸内環境パターンに前記第１の効果が見込める第２の成分を探索するステップと、
前記第２の成分において、前記第２の腸内環境パターンを取得するステップと、
前記第１および第２の腸内環境パターンのカバー率を算出するステップと、
前記第１および第２の成分を含有する組成物を製造するステップと、
により得られた、組成物における成分の選択方法。
［項目９］
所定の効果を有する２つ以上の成分を含有する、組成物の製造方法であって、
前記各成分が、所定の集団において、前記効果が期待できる対象者の割合を示すカバー率の合計が所定の割合以上になるように選択された、組成物の製造方法。
［項目１０］
所定の効果を有する２つ以上の成分を含有する、組成物の製造方法であって、
前記成分が、所定の集団において、前記各成分について設定された前記効果が期待できる腸内環境パターンの対象者の割合を示すカバー率の合計が所定の割合以上になるように選択された、組成物の製造方法。
［項目１１］
第１の効果が見込める第１の成分および第２の成分を含有し、
前記第１の成分は、前記第１の効果が見込める第１の腸内環境パターンのカバー率Ｘを有し、
前記第２の成分は、前記第１の効果が見込める第２の腸内環境パターンのカバー率Ｙを有し、
前記第１および第２の腸内環境パターンのカバー率の合計が所定の割合以上である、組成物の製造方法。
［項目１２］
第１の成分において、第１の効果が見込める第１の腸内環境パターンを取得するステップと、
前記第１の腸内環境パターンのカバー率を算出するステップと、
前記カバー率が基準値以上であるかを判断するするステップと、
第２の腸内環境パターンに前記第１の効果が見込める第２の成分を探索するステップと、
前記第２の成分において、前記第２の腸内環境パターンを取得するステップと、
前記第１および第２の腸内環境パターンのカバー率を算出するステップと、
前記第１および第２の成分を含有する組成物を製造するステップと、
により得られた、組成物の製造方法。
［項目１３］
第１の成分において、第１の効果が見込める第１の腸内環境パターンを取得する取得部と、
前記第１の腸内環境パターンのカバー率を算出する算出部と、
前記カバー率が基準値以上であるかを判断するする判断部と、
第２の腸内環境パターンに前記第１の効果が見込める第２の成分を探索する探索部と、
取得された情報を提供する情報提供部と、を備え、
前記取得部は、前記第２の成分において、前記第２の腸内環境パターンを取得し、
前記算出部は、前記第１および第２の腸内環境パターンのカバー率を算出する、情報処理システム。
［項目１４］
第１の成分において、第１の効果が見込める第１の腸内環境パターンを取得するステップと、
前記第１の腸内環境パターンのカバー率を算出するステップと、
前記カバー率が基準値以上であるかを判断するするステップと、
第２の腸内環境パターンに前記第１の効果が見込める第２の成分を探索するステップと、
前記第２の成分において、前記第２の腸内環境パターンを取得するステップと、
前記第１および第２の腸内環境パターンのカバー率を算出するステップと、
取得された情報を提供するステップと、
を有する、コンピュータによる情報処理方法。 The present invention includes, for example, the following configuration.
[Item 1]
A composition containing two or more components having a predetermined effect,
A composition in which each of the components is selected such that the total coverage rate, which indicates the proportion of subjects for whom the effect can be expected in a predetermined group, is equal to or higher than a predetermined proportion.
[Item 2]
A composition containing two or more components having a predetermined effect,
A composition in which the ingredients are selected such that the total coverage rate indicating the proportion of subjects with the intestinal environment pattern in which the effect set for each ingredient can be expected in a predetermined population is equal to or higher than a predetermined proportion. thing.
[Item 3]
Contains a first component and a second component that are expected to have the first effect,
The first component has a coverage rate X of a first intestinal environment pattern in which the first effect can be expected,
The second component has a coverage rate Y of a second intestinal environment pattern in which the first effect can be expected,
A composition in which the total coverage of the first and second intestinal environment patterns is equal to or higher than a predetermined ratio.
[Item 4]
obtaining a first intestinal environment pattern in which the first effect can be expected for the first ingredient;
calculating the coverage rate of the first intestinal environment pattern;
determining whether the coverage rate is equal to or higher than a reference value;
searching for a second component that is expected to have the first effect on a second intestinal environment pattern;
In the second component, acquiring the second intestinal environment pattern;
calculating the coverage of the first and second intestinal environment patterns;
producing a composition containing the first and second components;
A composition obtained by.
[Item 5]
A method for selecting components in a composition containing two or more components having a predetermined effect, the method comprising:
A selection method in which each of the components is selected such that a total coverage rate indicating the proportion of subjects for whom the effect can be expected in a predetermined group is equal to or higher than a predetermined proportion.
[Item 6]
A method for selecting components in a composition containing two or more components having a predetermined effect, the method comprising:
The ingredients are selected such that the total coverage rate indicating the proportion of subjects with the intestinal environment pattern in which the effect set for each ingredient can be expected in a predetermined population is equal to or higher than a predetermined proportion. Method.
[Item 7]
Contains a first component and a second component that are expected to have the first effect,
The first component has a coverage rate X of a first intestinal environment pattern in which the first effect can be expected,
The second component has a coverage rate Y of a second intestinal environment pattern in which the first effect can be expected,
A method for selecting components in a composition, wherein the total coverage of the first and second intestinal environment patterns is equal to or higher than a predetermined ratio.
[Item 8]
obtaining a first intestinal environment pattern in which the first effect can be expected for the first ingredient;
calculating the coverage rate of the first intestinal environment pattern;
determining whether the coverage rate is equal to or higher than a reference value;
searching for a second component that is expected to have the first effect on a second intestinal environment pattern;
In the second component, acquiring the second intestinal environment pattern;
calculating the coverage of the first and second intestinal environment patterns;
producing a composition containing the first and second components;
A method for selecting components in a composition obtained by
[Item 9]
A method for producing a composition containing two or more components having a predetermined effect, the method comprising:
A method for producing a composition, wherein each of the components is selected such that the total coverage rate, which indicates the proportion of subjects for whom the effect can be expected in a predetermined group, is equal to or higher than a predetermined proportion.
[Item 10]
A method for producing a composition containing two or more components having a predetermined effect, the method comprising:
A composition in which the ingredients are selected such that the total coverage rate indicating the proportion of subjects with the intestinal environment pattern in which the effect set for each ingredient can be expected in a predetermined population is equal to or higher than a predetermined proportion. How things are manufactured.
[Item 11]
Contains a first component and a second component that are expected to have the first effect,
The first component has a coverage rate X of a first intestinal environment pattern in which the first effect can be expected,
The second component has a coverage rate Y of a second intestinal environment pattern in which the first effect can be expected,
A method for producing a composition, wherein the total coverage of the first and second intestinal environment patterns is equal to or higher than a predetermined ratio.
[Item 12]
obtaining a first intestinal environment pattern in which the first effect can be expected for the first ingredient;
calculating the coverage rate of the first intestinal environment pattern;
determining whether the coverage rate is equal to or higher than a reference value;
searching for a second component that is expected to have the first effect on a second intestinal environment pattern;
In the second component, acquiring the second intestinal environment pattern;
calculating the coverage of the first and second intestinal environment patterns;
producing a composition containing the first and second components;
A method for producing a composition obtained by
[Item 13]
an acquisition unit that acquires a first intestinal environment pattern in which a first effect can be expected for the first component;
a calculation unit that calculates the coverage rate of the first intestinal environment pattern;
a determination unit that determines whether the coverage rate is equal to or higher than a reference value;
a search unit that searches for a second component that is expected to have the first effect on a second intestinal environment pattern;
an information provision unit that provides the acquired information;
The acquisition unit acquires the second intestinal environment pattern in the second component,
The information processing system, wherein the calculation unit calculates coverage rates of the first and second intestinal environment patterns.
[Item 14]
obtaining a first intestinal environment pattern in which the first effect can be expected for the first ingredient;
calculating the coverage rate of the first intestinal environment pattern;
determining whether the coverage rate is equal to or higher than a reference value;
searching for a second component that is expected to have the first effect on a second intestinal environment pattern;
In the second component, acquiring the second intestinal environment pattern;
calculating the coverage of the first and second intestinal environment patterns;
providing the obtained information;
An information processing method using a computer, comprising:
＜概要＞
所定の集団において、所定の成分を摂取することで所定の効果が期待できる対象者の割合を示す推定値を、カバー率（占有率）と定義することができる。 <Summary>
In a predetermined group, an estimated value indicating the proportion of subjects who can expect a predetermined effect by ingesting a predetermined ingredient can be defined as a coverage rate (occupancy rate).
所定の集団において、所定の成分を摂取することで所定の効果が期待できる対象者の割合を示す推定値を、カバー率（占有率）と定義することができる。 <Summary>
In a predetermined group, an estimated value indicating the proportion of subjects who can expect a predetermined effect by ingesting a predetermined ingredient can be defined as a coverage rate (occupancy rate).
所定の集団とは、例えば、人種（アジア人、ヨーロッパ人など）、国籍（日本人、中国人など）、性別（男性、女性など）、年齢（乳児、幼児、小学生、高齢者など）などにより設定した集団とすることができる。また、所定の老人ホームの入居者、所定の小学校の児童、所定の保育園の園児、所定の家族、所定のスポーツチーム、所定の企業の従業員などの集団を任意に設定することもできる。あるいは、便秘気味、尿酸値が高い、眠りが浅いと感じている、疾患予防に努めたいと考えている、所定の医薬品を服用中である、など、特定の体調や思考を有する集団であってもよい。さらに、これらの組み合わせにより設定された集団であってもよい。
Specified groups include, for example, race (Asian, European, etc.), nationality (Japanese, Chinese, etc.), gender (male, female, etc.), age (infants, toddlers, elementary school students, elderly, etc.), etc. The group can be set by Further, groups such as residents of a predetermined nursing home, children of a predetermined elementary school, children of a predetermined nursery school, a predetermined family, a predetermined sports team, and employees of a predetermined company can be set arbitrarily. Or, if you are a group of people with specific physical conditions or thoughts, such as those with a tendency to constipation, high uric acid levels, poor sleep, wanting to prevent diseases, or taking prescribed medicines. Good too. Furthermore, the group may be set by a combination of these.
例えば、上記のような機能性物質の一例として、腸内環境タイプＡのヒトに便通改善効果がある乳酸菌Ｘにより製造されたヨーグルトは、腸内環境タイプＢのヒトに対して便通改善効果はない、もしくは効果が低いと考えられるため、所定の集団（例えば、日本人）に対するカバー率は低くなる。そこで、そのヨーグルトのカバー率を上げるためには、腸内環境タイプＢのヒトに便通改善効果を発揮させるための別の成分（素材）をそのヨーグルトが含有するものとすればよい。
For example, as an example of the above-mentioned functional substances, yogurt produced by lactic acid bacteria X has the effect of improving bowel movement in people with type A intestinal environment, but it does not have the effect of improving bowel movement in people with type B intestinal environment. or because it is considered to be less effective, the coverage rate for a given group (for example, Japanese) will be low. Therefore, in order to increase the coverage rate of the yogurt, the yogurt may contain another component (material) that is effective in improving bowel movement in people with intestinal environment type B.
すなわち、乳酸菌Ｘが腸内環境タイプＢのヒトに対して便通改善効果がない場合であっても、腸内環境タイプＢのヒトに同様の便通改善効果という機能をもたらすと考えられる別の素材（例えば、乳酸菌Ｙ）を乳酸菌Ｘと共にヨーグルトを製造する際に用いることで、腸内環境タイプＡのヒトと腸内環境タイプＢの両タイプのヒトに便通改善効果をもたらすヨーグルトを提供することができ、そのヨーグルトの所定の集団に対する所定の効果のカバー率を上げることができる。
In other words, even if lactic acid bacteria For example, by using lactic acid bacteria (Y) together with lactic acid bacteria , it is possible to increase the coverage of the predetermined effect of the yogurt on the predetermined population.
このように、本発明は、新たな方法で成分を選択して組成物を設計することにより、所定の集団において、所定の効果に対するカバー率が高い機能性物質を提供するものである。
In this way, the present invention provides a functional substance that has a high coverage rate for a predetermined effect in a predetermined population by selecting components and designing a composition using a new method.
これは、薬剤やサプリメント、食品等の機能性物質を摂取した際の効果が、その人の腸内環境パターンの違いに基づいて個人ごとに異なるという知見に基づくものである。このような機能性物質を摂取した際に効果が得られる人を「レスポンダー」、効果が得られない人を「ノンレスポンダー」と定義することができる。
This is based on the knowledge that the effects of ingesting functional substances such as drugs, supplements, and foods vary from person to person based on differences in the person's intestinal environment pattern. Those who benefit from ingesting such functional substances can be defined as "responders," and those who do not experience such effects can be defined as "non-responders."
例えば、大麦を摂取した際、その次の食事による血糖値上昇が抑えられる「セカンドミール効果」があることが知られているが、この効果にはレスポンダーとノンレスポンダーが存在する。このレスポンダーとノンレスポンダーの違いには腸内細菌叢中のプレボテラ属細菌の比率が関係していると考えられており、レスポンダーはノンレスポンダーと比較してプレボテラ属細菌の比率が高い傾向にあることがわかっている。この場合、プレボテラ属細菌の比率が多い人は大麦摂取によってセカンドミール効果が得られる「レスポンダー」であり、少ない人はその効果が得られない「ノンレスポンダー」となる。
For example, it is known that when barley is ingested, there is a "second meal effect" that suppresses the rise in blood sugar levels caused by the next meal, but there are responders and non-responders to this effect. This difference between responders and non-responders is thought to be related to the proportion of Prevotella bacteria in the intestinal flora, with responders tending to have a higher proportion of Prevotella bacteria than non-responders. I know something. In this case, people with a high proportion of Prevotella bacteria are "responders" who can obtain the second meal effect by ingesting barley, and those with a low proportion are "non-responders" who cannot obtain this effect.
このような概念は、ヨーグルトのようなプロバイオティクスや機能性表示食品など、摂取する食品などの物質と、それによってもたらされる影響との間で普遍的に存在する概念であると考えられる。医薬品の場合も同様であり、例えば、がん治療薬として近年注目されている免疫チェックポイント阻害剤の効果が、患者の腸内細菌叢のパターンに依存することが報告され、腸内細菌叢のパターンが宿主免疫系に影響を与えることが理由であると考えられている。腸内環境は個々人で異なることから、有益な効果が期待されている食品（特定保健用食品や機能性表示食品などを含む）や医薬品などは、すべての人に一様な効果がもたらされる可能性は低く、レスポンダーとノンレスポンダーが存在することを認識する必要がある。
This concept is thought to be universal between substances such as foods we ingest, such as probiotics like yogurt and foods with functional claims, and the effects they bring. The same is true for pharmaceuticals; for example, it has been reported that the effects of immune checkpoint inhibitors, which have attracted attention in recent years as cancer treatment drugs, depend on the pattern of the patient's intestinal flora. The reason is thought to be that the pattern affects the host immune system. Since the intestinal environment differs from person to person, it is possible that foods (including foods for specified health uses and foods with functional claims) and medicines that are expected to have beneficial effects will have the same effect on all people. It is important to recognize that there are responders and non-responders.
また一方で、一部の食品やサプリメント、医薬品には、特定の腸内細菌や腸内細菌由来の代謝物質を増減させる効果があることが知られている。例えば、乳酸菌やビフィズス菌などを含むヨーグルトやぬか漬け、納豆などの発酵食品や整腸剤などのプロバイオティクスや、食物繊維やオリゴ糖を多く含むプレバイオティクスと呼ばれる食品やサプリメントは、腸内環境を変化させることが知られている。その他、運動習慣やアルコールの摂取、ストレス等の生活習慣によっても、腸内環境が変化することが知られている。
On the other hand, it is known that some foods, supplements, and medicines have the effect of increasing or decreasing specific intestinal bacteria or metabolic substances derived from intestinal bacteria. For example, fermented foods such as yogurt, bran pickles, and natto that contain lactic acid bacteria and bifidobacteria, probiotics such as intestinal regulators, and foods and supplements called prebiotics that contain a lot of dietary fiber and oligosaccharides can improve the intestinal environment. known to change. In addition, it is known that the intestinal environment changes due to lifestyle habits such as exercise habits, alcohol intake, and stress.
ここで、研究・調査により特定の機能性物質に対してレスポンダーである人に共通する腸内環境パターンを見出し、これを「応答性腸内環境パターン」としてデータベース化することができる。応答性腸内環境パターンを見出す調査方法は既知の方法により行うことができるが、例えば、以下のような方法で行うことができる。
Here, through research and investigation, it is possible to discover intestinal environment patterns common to people who are responders to specific functional substances, and create a database of these as "responsive intestinal environment patterns." The investigation method for finding a responsive intestinal environment pattern can be carried out by a known method, and for example, it can be carried out by the following method.
複数人の被験者に所定期間にわたって機能性物質を摂取させ、摂取後に期待された効果が得られたかをアンケートや検査により調査する。当該調査結果を必要に応じて任意の統計手法を用いて解析し、効果が得られた者（レスポンダー）と効果が得られなかった者（ノンレスポンダー）とを分類する。また、機能性物質の摂取前～摂取後のいずれかの時点における被験者の便検体を採取し、腸内細菌叢又は代謝物質を調べる。そして、レスポンダーとノンレスポンダーとの間で、相対存在比が有意に異なる腸内細菌又は便含量が有意に異なる代謝物質等を測定することによって、レスポンダーに共通する応答性腸内環境パターンを見出すことができる。
Multiple subjects are asked to ingest functional substances over a predetermined period of time, and surveys and tests are conducted to determine whether the expected effects are obtained after ingestion. The survey results are analyzed using arbitrary statistical methods as necessary, and those who have obtained an effect (responders) and those who have not obtained an effect (non-responders) are classified. In addition, a stool sample is collected from the subject at any time from before to after ingestion of the functional substance, and the intestinal flora or metabolic substances are examined. Then, by measuring intestinal bacteria with significantly different relative abundance ratios or metabolites with significantly different fecal content between responders and non-responders, we will discover responsive intestinal environment patterns common to responders. be able to.
本発明は、上記のように所定の集団において、所定の効果に対するカバー率が高い組成物を提供するものである。本明細書において、組成物とは、複数の成分を含むものを意味する。本実施形態に係る組成物の形態としては、例えば、医薬品や食品添加剤、サプリメント、食品などの形態を挙げることができる。医薬品や食品添加剤、サプリメントの形態とする場合、その剤型としては、例えば、散剤、錠剤、糖衣剤、カプセル剤、顆粒剤、ドライシロップ剤、液剤、シロップ剤、ドロップ剤、ドリンク剤等の固形または液状の剤型を挙げることができる。
As described above, the present invention provides a composition that has a high coverage rate for a predetermined effect in a predetermined population. As used herein, a composition means one containing multiple components. Examples of the form of the composition according to the present embodiment include forms such as pharmaceuticals, food additives, supplements, and foods. In the case of pharmaceuticals, food additives, and supplements, the dosage forms include solid forms such as powders, tablets, sugar-coated agents, capsules, granules, dry syrups, liquids, syrups, drops, and drinks. Alternatively, a liquid dosage form can be mentioned.
下記実施形態に係る組成物が食品の場合は、菓子や飲料、ヨーグルト、加工食品、健康食品、乳幼児食品などの通常の飲食物の形態を挙げることができる。飲食物の形態とする場合は、通常の製造過程で、有効成分を添加して製造することができる。摂取量は任意の量、任意の摂取期間とすることができる。
When the composition according to the embodiments below is a food, it can be in the form of ordinary food and drink such as confectionery, drinks, yogurt, processed foods, health foods, and infant foods. When it is in the form of a food or drink, it can be manufactured by adding active ingredients in a normal manufacturing process. The amount of intake can be any amount and any period of intake.
本実施形態に係る組成物をヒトや動物に対して用いる場合の摂取又は投与量は、例えば、１日あたり０．０１５ｇ／ｋｇ体重以上を挙げることができる。係る摂取量は、１日１回に限らず、複数回に分割して摂取してもよい。摂取量は任意の量、任意の摂取期間とすることができる。
When the composition according to the present embodiment is used for humans or animals, the intake or administration amount can be, for example, 0.015 g/kg or more per day. The intake amount is not limited to once a day, but may be divided into multiple doses. The amount of intake can be any amount and any period of intake.
例えば、組成物がヨーグルトの場合、所定の成分は乳酸菌であることができ、所定の効果としては便通改善が挙げられる。上記のヨーグルトの例に当てはめると、乳酸菌Ｘにより製造されたヨーグルトに対するノンレスポンダー（腸内環境タイプＢ）は乳酸菌Ｙに対するレスポンダーであるため、乳酸菌Ｘと乳酸菌Ｙを含有するヨーグルトとすることで、腸内環境タイプＡのヒトと腸内環境タイプＢのヒトの両方がそのヨーグルトのレスポンダーとなり、その結果、そのヨーグルトのカバー率を上げるものである。すなわち、本発明では、乳酸菌Ｘにより製造されたヨーグルトに対するノンレスポンダーを、乳酸菌Ｘとは別の素材を加えることによって、レスポンダーにすることができ、これによりそのヨーグルトのカバー率を上げるものである。
For example, when the composition is yogurt, the predetermined component can be lactic acid bacteria, and the predetermined effect includes improving bowel movements. Applying the above yogurt example, non-responders (intestinal environment type B) to yogurt produced by lactic acid bacteria X are responders to lactic acid bacteria Y, so by making yogurt containing lactic acid bacteria X and lactic acid bacteria Y, Both people with intestinal environment type A and people with intestinal environment type B become responders to the yogurt, and as a result, the coverage rate of the yogurt increases. That is, in the present invention, non-responders to yogurt produced by lactic acid bacteria X can be made into responders by adding a material other than lactic acid bacteria X, thereby increasing the coverage of the yogurt. .
この例において、便通改善効果を得るための乳酸菌以外の成分としては、例えば、食物繊維やオリゴ糖であることができ、ビタミン類やミネラル類等の他の物質であることができる。
In this example, the components other than lactic acid bacteria to obtain the effect of improving bowel movements may be, for example, dietary fiber or oligosaccharides, or other substances such as vitamins or minerals.
本明細書において「腸内環境パターン」とは、特定の腸内細菌の有無、及び相対存在比率、腸内細菌間のバランス、腸内代謝物質の有無、含有量、代謝物質間のバランス、便中タンパク質（消化酵素、抗菌ペプチド、ホルモン物質等を含むがこれに限られない）の有無や含有量、ＩｇＡなどの免疫関連物質の有無や含有量、便性状（例えば水分含量、硬さ、色など）およびこれらの組合せを指す。なお、前記腸内細菌はバクテリアに限定されるものではなく、古細菌、真菌、ウイルス（ファージ）を含むものとする。また、前記腸内代謝物質は腸内細菌が産生する代謝物質、腸内細菌の死菌体、食物残渣、宿主が分泌する物質などを含むものであり、主に便中から検出されるが、腸内容物など便以外から検出されてもよい。前記便中タンパク質は、腸内細菌が産生するタンパク質、食物残渣、宿主が分泌する物質（消化酵素、免疫グロブリン、抗菌ペプチド等）を含むものであり、主に便中から検出されるが、腸内容物など便以外から検出されてもよい。
In this specification, "intestinal environment pattern" refers to the presence or absence of specific intestinal bacteria, relative abundance ratio, balance among intestinal bacteria, presence or absence of intestinal metabolites, content, balance among metabolites, stool Presence and content of intermediate proteins (including but not limited to digestive enzymes, antibacterial peptides, hormonal substances, etc.), presence and content of immune-related substances such as IgA, stool properties (e.g. water content, hardness, color) etc.) and combinations thereof. Note that the intestinal bacteria are not limited to bacteria, but include archaea, fungi, and viruses (phages). In addition, the intestinal metabolic substances include metabolic substances produced by intestinal bacteria, dead intestinal bacteria, food residue, substances secreted by the host, etc., and are mainly detected in stool. It may also be detected in other than stool, such as intestinal contents. The above-mentioned fecal proteins include proteins produced by intestinal bacteria, food residues, and substances secreted by the host (digestive enzymes, immunoglobulins, antibacterial peptides, etc.), and are mainly detected in feces. It may also be detected from contents other than stool.
また、本明細書において「機能性物質」とは、摂取した場合に所定の効果をもたらすことが期待される食品（飲料も含む。以下同じ）であり、その形態は保健機能食品、健康補助食品、機能性表示食品、特定保健用食品又は特別用途食品である場合を含む。さらに「機能性物質」には、医薬品、サプリメントなども含む。なお、「食品」は、食材や、食材に含まれる特定の栄養素も含む。また、「医薬品」、「サプリメント」は、それらに含まれる有効成分（化合物）であってもよい。また、機能性物質が持つ所定の効果とは、例えば痩せる、太りにくくなる、血糖値が下がる、耐糖能が向上する、便通が良くなる、免疫力が向上する、アトピー・アレルギーが緩和される、肌の状態が良くなる、睡眠の質が向上する、記憶力が改善する、運動機能が改善する、抗鬱作用がある、など、摂取者の身体的・精神的な状態を変化させるものであればよい。なお、本実施形態における機能性物質の摂取者はヒトに限らず家畜やペット等の動物または蜂やカイコなどの産業動物にも適用可能である。
In addition, the term "functional substance" as used herein refers to food (including beverages; the same applies hereinafter) that is expected to have a predetermined effect when ingested; , including cases where the food is a food with functional claims, a food for specified health uses, or a food for special purposes. Furthermore, "functional substances" include medicines, supplements, etc. Note that "food" includes ingredients and specific nutrients contained in ingredients. Furthermore, "medicinal products" and "supplements" may refer to active ingredients (compounds) contained therein. In addition, the prescribed effects of functional substances include, for example, weight loss, resistance to gaining weight, lowering blood sugar levels, improving glucose tolerance, improving bowel movements, improving immunity, alleviating atopic dermatitis and allergies, etc. If it changes the physical or mental state of the person taking it, such as improving skin condition, improving sleep quality, improving memory, improving motor function, or having antidepressant effects. good. Note that the person taking the functional substance in this embodiment is not limited to humans, but can also be applied to animals such as livestock and pets, or industrial animals such as bees and silkworms.
＜構成＞
本発明の一実施形態に係る情報処理システムは、例えば、所定の集団において、所定の効果に対するカバー率が高い組成物を製造するための情報をユーザ端末に提供するものである。図１に示されるように、本実施形態に係るシステムは、サーバ１を備える。サーバ１は、インターネット等のネットワークを介してユーザ端末２が接続される。図１には、説明の便宜のために、１つのユーザ端末２が図示されているが、複数の端末が本システムのネットワークに接続可能である。 <Configuration>
An information processing system according to an embodiment of the present invention provides a user terminal with information for producing a composition that has a high coverage rate for a predetermined effect in a predetermined group, for example. As shown in FIG. 1, the system according to this embodiment includes a server 1. A user terminal 2 is connected to the server 1 via a network such as the Internet. Although one user terminal 2 is illustrated in FIG. 1 for convenience of explanation, a plurality of terminals can be connected to the network of this system.
本発明の一実施形態に係る情報処理システムは、例えば、所定の集団において、所定の効果に対するカバー率が高い組成物を製造するための情報をユーザ端末に提供するものである。図１に示されるように、本実施形態に係るシステムは、サーバ１を備える。サーバ１は、インターネット等のネットワークを介してユーザ端末２が接続される。図１には、説明の便宜のために、１つのユーザ端末２が図示されているが、複数の端末が本システムのネットワークに接続可能である。 <Configuration>
An information processing system according to an embodiment of the present invention provides a user terminal with information for producing a composition that has a high coverage rate for a predetermined effect in a predetermined group, for example. As shown in FIG. 1, the system according to this embodiment includes a server 1. A user terminal 2 is connected to the server 1 via a network such as the Internet. Although one user terminal 2 is illustrated in FIG. 1 for convenience of explanation, a plurality of terminals can be connected to the network of this system.
＜ハードウェア構成＞
本実施形態において、サーバ１とユーザ端末２とは、以下のようなハードウェア構成を有する。なお、以下の構成は一例であり、これ以外の構成を有していても良い。 <Hardware configuration>
In this embodiment, the server 1 and the user terminal 2 have the following hardware configurations. Note that the following configuration is an example, and other configurations may be used.
本実施形態において、サーバ１とユーザ端末２とは、以下のようなハードウェア構成を有する。なお、以下の構成は一例であり、これ以外の構成を有していても良い。 <Hardware configuration>
In this embodiment, the server 1 and the user terminal 2 have the following hardware configurations. Note that the following configuration is an example, and other configurations may be used.
＜サーバ１＞
図２は、サーバ１のハードウェア構成を示す図である。サーバ１は、例えば、ワークステーションやパーソナルコンピュータのような汎用コンピュータとしてもよいし、或いはクラウド・コンピューティングによって論理的に実現されてもよい。 <Server 1>
FIG. 2 is a diagram showing the hardware configuration of the server 1. The server 1 may be, for example, a general-purpose computer such as a workstation or a personal computer, or may be logically realized by cloud computing.
図２は、サーバ１のハードウェア構成を示す図である。サーバ１は、例えば、ワークステーションやパーソナルコンピュータのような汎用コンピュータとしてもよいし、或いはクラウド・コンピューティングによって論理的に実現されてもよい。 <Server 1>
FIG. 2 is a diagram showing the hardware configuration of the server 1. The server 1 may be, for example, a general-purpose computer such as a workstation or a personal computer, or may be logically realized by cloud computing.
サーバ１は、少なくとも、プロセッサ１０、メモリ１１、ストレージ１２、送受信部１３、入出力部１４等を備え、これらはバス１５を通じて相互に電気的に接続される。
The server 1 includes at least a processor 10, a memory 11, a storage 12, a transmitting/receiving section 13, an input/output section 14, etc., which are electrically connected to each other via a bus 15.
プロセッサ１０は、サーバ１全体の動作を制御し、各要素間におけるデータの送受信の制御、及びアプリケーションの実行に必要な情報処理等を行う演算装置である。例えばプロセッサ１０はＣＰＵ（Ｃｅｎｔｒａｌ Ｐｒｏｃｅｓｓｉｎｇ Ｕｎｉｔ）であり、ストレージ１２に格納されメモリ１１に展開されたプログラム等を実行して各情報処理を実施する。
The processor 10 is an arithmetic device that controls the overall operation of the server 1, controls the transmission and reception of data between each element, and performs information processing necessary for executing applications. For example, the processor 10 is a CPU (Central Processing Unit), and executes programs stored in the storage 12 and developed in the memory 11 to perform various information processing.
メモリ１１は、ＤＲＡＭ（Ｄｙｎａｍｉｃ Ｒａｎｄｏｍ Ａｃｃｅｓｓ Ｍｅｍｏｒｙ）等の揮発性記憶装置で構成される主記憶と、フラッシュメモリやＨＤＤ（Ｈａｒｄ Ｄｉｓｃ Ｄｒｉｖｅ）等の不揮発性記憶装置で構成される補助記憶と、を含む。メモリ１１は、プロセッサ１０のワークエリア等として使用され、また、サーバ１の起動時に実行されるＢＩＯＳ（Ｂａｓｉｃ Ｉｎｐｕｔ ／ Ｏｕｔｐｕｔ Ｓｙｓｔｅｍ）、及び各種設定情報等を格納する。
The memory 11 includes a main memory configured with a volatile storage device such as a DRAM (Dynamic Random Access Memory), and an auxiliary memory configured with a non-volatile storage device such as a flash memory or an HDD (Hard Disc Drive). . The memory 11 is used as a work area for the processor 10, and also stores a BIOS (Basic Input/Output System) executed when the server 1 is started, various setting information, and the like.
ストレージ１２は、アプリケーション・プログラム等の各種プログラムを格納する。各処理に用いられるデータを格納したデータベースがストレージ１２に構築されていてもよい。
The storage 12 stores various programs such as application programs. A database storing data used for each process may be constructed in the storage 12.
送受信部１３は、サーバ１をネットワーク３に接続する。なお、送受信部１３は、Ｂｌｕｅｔｏｏｔｈ（登録商標）及びＢＬＥ（Ｂｌｕｅｔｏｏｔｈ Ｌｏｗ Ｅｎｅｒｇｙ）の近距離通信インタフェースを備えていてもよい。
The transmitting/receiving unit 13 connects the server 1 to the network 3. Note that the transmitting/receiving unit 13 may include a short-range communication interface of Bluetooth (registered trademark) and BLE (Bluetooth Low Energy).
入出力部１４は、必要に応じて使用するキーボード・マウス類等の情報入力機器、およびディスプレイ等の出力機器である。
The input/output unit 14 is information input devices such as a keyboard and mouse, and output devices such as a display, which are used as necessary.
バス１５は、上記各要素に共通に接続され、例えば、アドレス信号、データ信号及び各種制御信号を伝達する。
The bus 15 is commonly connected to each of the above elements and transmits, for example, address signals, data signals, and various control signals.
＜ユーザ端末２＞
ユーザ端末２は、サーバ１と通信を介して情報処理を実行する。ユーザ端末２は、例えば、組成物を製造するシステムを制御するための端末であることができる。ユーザ端末２は、例えば、ワークステーションやパーソナルコンピュータのような汎用コンピュータであってもよいし、スマートフォン等の携帯通信機器等であってもよい。 <User terminal 2>
The user terminal 2 executes information processing through communication with the server 1. The user terminal 2 can be, for example, a terminal for controlling a system for manufacturing a composition. The user terminal 2 may be, for example, a general-purpose computer such as a workstation or a personal computer, or a mobile communication device such as a smartphone.
ユーザ端末２は、サーバ１と通信を介して情報処理を実行する。ユーザ端末２は、例えば、組成物を製造するシステムを制御するための端末であることができる。ユーザ端末２は、例えば、ワークステーションやパーソナルコンピュータのような汎用コンピュータであってもよいし、スマートフォン等の携帯通信機器等であってもよい。 <User terminal 2>
The user terminal 2 executes information processing through communication with the server 1. The user terminal 2 can be, for example, a terminal for controlling a system for manufacturing a composition. The user terminal 2 may be, for example, a general-purpose computer such as a workstation or a personal computer, or a mobile communication device such as a smartphone.
図３は、本発明のシステムにおけるサーバ１のソフトウェア構成例を示す図である。サーバ１は、取得部１１１、算出部１１２、判断部１１３、探索部１１４、情報提供部１１５、応答性腸内環境情報記憶部１２１、カバー率記憶部１２２、取得情報記憶部１２３、付加情報記憶部１２４を備えることができる。
FIG. 3 is a diagram showing an example of the software configuration of the server 1 in the system of the present invention. The server 1 includes an acquisition section 111, a calculation section 112, a judgment section 113, a search section 114, an information provision section 115, a responsive intestinal environment information storage section 121, a coverage storage section 122, an acquired information storage section 123, and an additional information storage section. 124.
なお、取得部１１１、算出部１１２、判断部１１３、探索部１１４、情報提供部１１５は、サーバが備えるプロセッサ１０がストレージ１２に記憶されているプログラムをメモリ１１に読み出して実行することにより実現され、応答性腸内環境情報記憶部１２１、カバー率記憶部１２２、取得情報記憶部１２３、付加情報記憶部１２４は、メモリ１１及びストレージ１２の少なくともいずれかにより提供される記憶領域の一部として実現される。
Note that the acquisition unit 111, the calculation unit 112, the determination unit 113, the search unit 114, and the information provision unit 115 are realized by the processor 10 included in the server reading a program stored in the storage 12 into the memory 11 and executing it. , the responsive intestinal environment information storage unit 121, the coverage storage unit 122, the acquired information storage unit 123, and the additional information storage unit 124 are realized as part of the storage area provided by at least one of the memory 11 and the storage 12. be done.
応答性腸内環境情報記憶部１２１は、特定の機能性物質と、当該機能性物質の効果を得ることのできる応答性腸内環境パターンの特徴との組み合わせを含む。すなわち、過去の研究により、機能性物質の効果を得ることができるレスポンダーに共通する腸内環境パターンが明らかになっている場合に、当該レスポンダーに共通する腸内環境パターンの特徴を「応答性腸内環境パターン」としてデータベース化したものである。
The responsive intestinal environment information storage unit 121 includes a combination of a specific functional substance and a characteristic of a responsive intestinal environment pattern that can obtain the effects of the functional substance. In other words, if past research has revealed a common intestinal environment pattern among responders who can obtain the effects of functional substances, the characteristics of the intestinal environment pattern common to the responders are called "responsive intestinal environment". It has been compiled into a database as ``Internal Environmental Patterns''.
図４は、応答性腸内環境情報記憶部１２１に記憶された応答性腸内環境情報の構成例である。応答性腸内環境情報は、機能性物質ごとに付与されたＩＤに紐づけて、機能性物質のカテゴリ情報（食品、サプリメント、医薬品など）、機能性物質の摂取によって得られる効果（便秘が解消する、痩せる、耐糖能が上がる、など）、及び応答性腸内環境パターン情報を含むことができる。応答性腸内環境パターン情報とは、特定の腸内細菌の有無又は存在量・相対存在比率、腸内細菌間のバランス（特定の腸内細菌同士の存在比率など）、腸内代謝物質の有無、含有量、代謝物質間のバランス、便中タンパク質の有無や含有量、便性状（例えば水分含量、硬さ、色など）等であってよい。また、腸内細菌はその属（プレボテラ属細菌など）や種（プレボテラ コプリなど）等、特定の方法は問わない。
FIG. 4 is a configuration example of the responsive intestinal environment information stored in the responsive intestinal environment information storage unit 121. Responsive intestinal environment information is linked to the ID assigned to each functional substance, and includes information on the category of the functional substance (foods, supplements, medicines, etc.), and the effects obtained by ingesting the functional substance (relieves constipation). weight loss, improved glucose tolerance, etc.) and responsive intestinal environment pattern information. Responsive intestinal environment pattern information includes the presence, abundance, and relative abundance ratio of specific intestinal bacteria, the balance among intestinal bacteria (existence ratio of specific intestinal bacteria, etc.), and the presence or absence of intestinal metabolites. , content, balance between metabolites, presence or absence of protein in stool, content, stool properties (for example, water content, hardness, color, etc.). In addition, the specific method used for intestinal bacteria, such as its genus (such as Prevotella bacteria) and species (such as Prevotella copuli), does not matter.
また、腸内細菌の相対存在比率や腸内細菌間バランス、代謝物質の含有量や代謝物質間バランスなどは、レスポンダーであると判断する範囲を数値（閾値）によって規定することができる。閾値は、当該機能性物質を摂取した場合に効果がある群とない群とを判別するためのカットオフ値であり、適宜定めることができる。前記カットオフ値は、決定木、ランダムフォレスト、ロジスティック回帰等の機械学習アルゴリズムを適宜選択して算出してもよいし、効果がある群とない群の値の分布から適宜判断してもよい。より具体的には、例えば、感度と偽陽性率（１－特異度）の関係を、ＲＯＣ分析することにより求めることができる。
In addition, for the relative abundance ratio of intestinal bacteria, the balance between intestinal bacteria, the content of metabolites, the balance between metabolites, etc., the range for determining a responder can be defined by numerical values (threshold values). The threshold value is a cutoff value for distinguishing between a group that is effective and a group that is not effective when ingesting the functional substance, and can be determined as appropriate. The cutoff value may be calculated by appropriately selecting a machine learning algorithm such as a decision tree, random forest, or logistic regression, or may be determined as appropriate from the distribution of values of the effective group and the non-effective group. More specifically, for example, the relationship between sensitivity and false positive rate (1-specificity) can be determined by ROC analysis.
感度とは、例えば、真の状態が増加する群である予測対象を正しく増加する群であると予測している割合である。特異度とは、真の状態が増加しない群である予測対象を正しく増加しない群であると予測している割合である。ＲＯＣ分析においては、まず、カットオフ値を連続的に変化させたときの、感度と偽陽性率の値を求める。そして、縦軸（Ｙ軸）を感度とし、横軸（Ｘ軸）を偽陽性率とするグラフ上に、求めた感度および偽陽性率の値をプロットし、当該プロットした点の中から、感度１、特異度０の点に最も近い点を選択する方法、すなわち（１－感度）２＋偽陽性率２が最小になるような感度および特異度の組合せを決定する。このように決定した感度および特異度の組合せに対応するカットオフ値を、最終的なカットオフ値として設定することができる。なお、感度および特異度の組合せの決定の仕方は、前述した（１－感度）２＋偽陽性率２が最小になるような組合せに決定するという方法に限定されず、例えば、感度と特異度の積が最大になるような組合せに決定するという方法であってもよいし、（感度＋特異度）÷２が最大になるような組合せに決定するという方法であってもよい。
Sensitivity is, for example, the rate at which a prediction target, which is a group whose true state increases, is correctly predicted to be a group whose true state increases. Specificity is the rate at which a prediction target whose true state is a group that does not increase is correctly predicted to be a group that does not increase. In the ROC analysis, first, the values of sensitivity and false positive rate are determined when the cutoff value is continuously changed. Then, plot the obtained sensitivity and false positive rate values on a graph where the vertical axis (Y axis) is the sensitivity and the horizontal axis (X axis) is the false positive rate, and from among the plotted points, the sensitivity 1. A method of selecting the point closest to the point with specificity 0, that is, determining a combination of sensitivity and specificity that minimizes (1-sensitivity) 2 + false positive rate 2 . The cutoff value corresponding to the combination of sensitivity and specificity determined in this way can be set as the final cutoff value. Note that the method for determining the combination of sensitivity and specificity is not limited to the method of determining the combination that minimizes (1-sensitivity) 2 + false positive rate 2 , for example, The combination may be determined to maximize the product of , or the combination may be determined to maximize (sensitivity + specificity) ÷ 2.
カバー率記憶部１２２は、所定の集団において所定の効果を有する成分ごとのカバー率を所定の応答性腸内環境パターンと共に記憶する。図５は、所定の効果を有する食品におけるカバー率記憶部１２２に記憶されるカバー率リストの構成例である。カバー率リストは、各効果等の識別情報に対して紐づけて、成分ごとのカバー率と応答性腸内環境パターンの情報を含むことができる。例えば、効果ａを有する成分としては成分Ａ－Ｄがあり、各成分に固有のカバー率と応答性腸内環境パターンが紐づけられている。なお、前記所定の集団とは異なる所定の集団を対象とする場合、前記カバー率と前記応答性腸内環境パターンは、異なる内容になると考えられる。
The coverage storage unit 122 stores the coverage rate for each component that has a predetermined effect in a predetermined population together with a predetermined responsive intestinal environment pattern. FIG. 5 is a configuration example of a coverage list stored in the coverage storage unit 122 for foods having a predetermined effect. The coverage list can include information on the coverage rate and responsive intestinal environment pattern for each component in association with identification information such as each effect. For example, components having effect a include components A to D, and each component is associated with a unique coverage rate and responsive intestinal environment pattern. In addition, when targeting a predetermined group different from the predetermined group, the coverage rate and the responsive intestinal environment pattern are considered to have different contents.
取得情報記憶部１２３は、取得部１１１が取得した情報を記憶する。取得情報記憶部１２３に記憶された情報は、情報提供部１１５によってユーザ端末２等に提供される。取得された情報は、例えば、取得部１１１で取得された所定の集団における所定の効果と、その所定の効果を見込める腸内環境パターンに関する情報、算出部１１２で算出されたカバー率、判断部１１３で判断された結果、探索部１１４で取得された情報である。
The acquired information storage unit 123 stores information acquired by the acquisition unit 111. The information stored in the acquired information storage unit 123 is provided to the user terminal 2 and the like by the information providing unit 115. The acquired information includes, for example, a predetermined effect in a predetermined group obtained by the obtaining unit 111 , information regarding the intestinal environment pattern in which the predetermined effect can be expected, a coverage rate calculated by the calculating unit 112 , and the determining unit 113 This is the information obtained by the search unit 114 as a result of the determination.
付加情報記憶部１２４は、例えば、上記取得情報に付加する情報を記憶する。付加情報は、例えば、各成分が有する他の効果の情報や、その成分の入手先、その成分を含有する組成物に適した形態やその製造方法であることができる。その形態が食品や食材である場合には、当該食材が含まれる食品や、食材を使ったレシピ情報であることができる。また、その組成物を摂取する頻度や量であってもよく、組成物がサプリメントや医薬品である場合には、当該サプリメントや医薬品の用量・用法などの使用上の注意などを含んでもよい。また、付加情報記憶部１２４は、成分の性状に関する情報、例えば、成分が水溶性、粉状、固形、液体である、温度の条件（例えば、失活する温度、凝固する温度等）を含むことができる。このような情報をデータベースにおいて付加しておくことによって、成分を選択するときの精度を向上させることができる。
The additional information storage unit 124 stores, for example, information added to the above-mentioned acquired information. The additional information can be, for example, information on other effects that each component has, where the component is obtained, a form suitable for a composition containing the component, and a manufacturing method thereof. When the form is a food or a food ingredient, it can be a food containing the food or recipe information using the food. It may also include the frequency and amount of ingestion of the composition, and if the composition is a supplement or medicine, it may also include precautions for use such as the dosage and usage of the supplement or medicine. Further, the additional information storage unit 124 may include information regarding the properties of the component, such as whether the component is water-soluble, powder, solid, or liquid, and temperature conditions (for example, deactivation temperature, solidification temperature, etc.). Can be done. By adding such information in the database, accuracy when selecting components can be improved.
取得部１１１は、組成物が含有することとなる複数の成分における、所定の効果を見込める腸内環境パターンを取得する。すなわち、所定の集団における所定の効果と、その所定の効果を見込める腸内環境パターンに関するデータを取得する。取得部１１１は、解析済みの腸内細菌パターン情報をユーザ端末２やサーバ１内（例えば応答性腸内環境情報記憶部１２１やカバー率記憶部１２２など）、若しくは別のデータサーバを介して入手してもよい。また、臨床試験で取得してもよい。
The acquisition unit 111 acquires intestinal environment patterns in which a predetermined effect can be expected in a plurality of components that the composition will contain. That is, data regarding a predetermined effect in a predetermined population and an intestinal environment pattern in which the predetermined effect can be expected is obtained. The acquisition unit 111 acquires the analyzed intestinal bacteria pattern information from the user terminal 2 or the server 1 (for example, the responsive intestinal environment information storage unit 121 or the coverage storage unit 122), or from another data server. You may. Alternatively, it may be obtained through a clinical trial.
算出部１１２は、取得した腸内環境パターンのカバー率を算出する。算出部１１２は、腸内環境パターンを取得するたびにカバー率を算出してもよく、また、カバー率記憶部１２２などのデータベースからカバー率を取得してもよい。算出部１１２は、算出したカバー率を判断部１１３に伝える。
The calculation unit 112 calculates the coverage rate of the acquired intestinal environment pattern. The calculation unit 112 may calculate the coverage rate each time an intestinal environment pattern is acquired, or may acquire the coverage rate from a database such as the coverage storage unit 122. The calculation unit 112 transmits the calculated coverage rate to the determination unit 113.
判断部１１３は、算出されたカバー率が基準値（例えば、９０％）以上かどうかを判断する。基準値は、適宜設定することができる。判断部１１３は、カバー率が基準値以上かどうかを情報提供部１１５に伝える。
The determining unit 113 determines whether the calculated coverage rate is equal to or higher than a reference value (for example, 90%). The reference value can be set as appropriate. The determining unit 113 informs the information providing unit 115 whether the coverage rate is equal to or higher than the reference value.
探索部１１４は、カバー率記憶部１２２に記憶された情報から、所定の効果が見込める成分を探索する。例えば、探索部１１４は、成分Ａの効果ａが見込める腸内環境パターンＸがある場合に、腸内環境パターンＸ以外の腸内環境パターンに効果ａが見込める成分Ａ以外の他の成分を探索する。
The search unit 114 searches for a component that can be expected to have a predetermined effect from the information stored in the coverage storage unit 122. For example, when there is an intestinal environment pattern X in which the effect a of component A can be expected, the search unit 114 searches for other components other than component A that can be expected to have the effect a in intestinal environment patterns other than the intestinal environment pattern X. .
情報提供部１１５は、取得され、取得情報記憶部１２３に記憶された情報を、例えば、ユーザ端末２に提供する。取得された情報は、例えば、取得部１１１で取得された所定の集団における所定の効果と、その所定の効果を見込める腸内環境パターンに関する情報、算出部１１２で算出されたカバー率、判断部１１３で判断された結果、探索部１１４で取得された情報である。必要に応じて、各情報に上記の付加情報を追加してもよい。
The information providing unit 115 provides the information acquired and stored in the acquired information storage unit 123 to the user terminal 2, for example. The acquired information includes, for example, a predetermined effect in a predetermined group obtained by the obtaining unit 111 , information regarding the intestinal environment pattern in which the predetermined effect can be expected, a coverage rate calculated by the calculating unit 112 , and the determining unit 113 This is the information obtained by the search unit 114 as a result of the determination. The above additional information may be added to each piece of information as necessary.
＜動作フロー＞
以下、本発明の一実施形態に係る情報処理システムにおけるサーバ１の動作フローについて図６をもとに説明する。図６は、サーバ１において実行される組成物における成分の選択を行う処理の流れを示す図である <Operation flow>
The operation flow of the server 1 in the information processing system according to an embodiment of the present invention will be described below with reference to FIG. 6. FIG. 6 is a diagram showing the flow of processing for selecting components in a composition executed in the server 1.
以下、本発明の一実施形態に係る情報処理システムにおけるサーバ１の動作フローについて図６をもとに説明する。図６は、サーバ１において実行される組成物における成分の選択を行う処理の流れを示す図である <Operation flow>
The operation flow of the server 1 in the information processing system according to an embodiment of the present invention will be described below with reference to FIG. 6. FIG. 6 is a diagram showing the flow of processing for selecting components in a composition executed in the server 1.
まず、取得部１１１は、所定の効果ａを有する成分Ａが、効果ａをもたらすと考えられる腸内環境パターンＸを取得する（Ｓ１０１）。腸内環境パターンＸは、応答性腸内環境情報記憶部１２１に記憶された応答性腸内環境情報やその他のデータベース、文献情報、臨床試験の結果などから取得することができる。
First, the acquisition unit 111 acquires an intestinal environment pattern X in which a component A having a predetermined effect a is considered to bring about an effect a (S101). The intestinal environment pattern X can be acquired from the responsive intestinal environment information stored in the responsive intestinal environment information storage unit 121, other databases, literature information, clinical test results, and the like.
算出部１１２は、取得した腸内環境パターンＸのカバー率を算出する（Ｓ１０２）。カバー率の算出は、腸内環境パターンを取得するたびにカバー率を算出してもよく、また、カバー率記憶部１２２などのデータベースからカバー率を取得してもよい。もしくは、この時に各々の腸内環境パターンが既知である人（または動物など）たちから構成される新たな所定の集団の情報が与えられてもよく、前記所定の集団に対する腸内環境パターンＸ＋Ｙのカバー率を算出してもよい。算出されたカバー率が基準値（例えば、９０％）以上かどうかを判断し、基準値を満たさない場合（Ｓ１０３＝Ｎｏ）はカバー率が低いと判断して、Ｓ１０４に進む。一方で、カバー率が基準値以上の場合（Ｓ１０３＝Ｙｅｓ）、Ｓ１０８に進む。
The calculation unit 112 calculates the coverage rate of the acquired intestinal environment pattern X (S102). The coverage rate may be calculated each time an intestinal environment pattern is acquired, or the coverage rate may be acquired from a database such as the coverage storage unit 122. Alternatively, at this time, information on a new predetermined group consisting of people (or animals, etc.) whose intestinal environment patterns are known may be given, and the intestinal environment pattern X+Y for the predetermined group may be given. A coverage rate may also be calculated. It is determined whether the calculated coverage ratio is equal to or higher than a reference value (for example, 90%), and if the reference value is not satisfied (S103=No), the coverage ratio is determined to be low and the process proceeds to S104. On the other hand, if the coverage rate is equal to or greater than the reference value (S103=Yes), the process advances to S108.
探索部１１４は、カバー率記憶部１２２に記憶された情報から、効果ａが見込める他の成分を探索する（Ｓ１０４）。効果ａが見込める他の成分として成分Ｂが該当した場合、成分Ｂが、効果ａをもたらすと考えられる腸内環境パターンＹを取得する（Ｓ１０５）。腸内環境パターンＹは、腸内環境パターンＸと同様に、応答性腸内環境情報記憶部１２１に記憶された応答性腸内環境情報やその他のデータベース、文献情報、臨床試験の結果などから取得することができる。
The search unit 114 searches for other components that can be expected to have effect a from the information stored in the coverage storage unit 122 (S104). When component B is found to be another component that can be expected to have effect a, an intestinal environment pattern Y in which component B is thought to bring about effect a is acquired (S105). Similar to the intestinal environment pattern X, the intestinal environment pattern Y is obtained from the responsive intestinal environment information stored in the responsive intestinal environment information storage unit 121, other databases, literature information, clinical trial results, etc. can do.
算出部１１２は、取得した腸内環境パターンＸ＋Ｙのカバー率を算出する（Ｓ１０６）。カバー率は、腸内環境パターンＸのカバー率と、腸内環境パターンＹのカバー率の合計であってもよく、それぞれのカバー率またはカバー率の合計に所定の係数を掛けたものであってもよく、あるいは腸内環境パターンＸと腸内環境パターンＹに重複する部分がある場合はそれを考慮した数値でも良い。カバー率は、このステップで算出してもよく、また、カバー率記憶部１２２に記憶されたカバー率リストなどのデータベースからカバー率を取得してもよい。なお、ここでカバー率を計算する対象の集団は、Ｓ１０２で対象とした集団であることが原則だが、この時に各々の腸内環境パターンが既知である人（または動物など）たちから構成される新たな所定の集団の情報が与えられてもよく、前記所定の集団に対する腸内環境パターンＸ＋Ｙのカバー率を算出してもよい。
The calculation unit 112 calculates the coverage rate of the acquired intestinal environment pattern X+Y (S106). The coverage rate may be the sum of the coverage rate of intestinal environment pattern Alternatively, if there is an overlap between the intestinal environment pattern X and the intestinal environment pattern Y, the value may be a value that takes this into consideration. The coverage rate may be calculated in this step, or may be obtained from a database such as a coverage list stored in the coverage storage unit 122. Note that the target population for calculating the coverage rate here is, in principle, the same as the target population in S102, but it is composed of people (or animals, etc.) whose intestinal environment patterns are known at this time. Information on a new predetermined group may be given, and the coverage rate of the intestinal environment pattern X+Y for the predetermined group may be calculated.
次に、算出されたカバー率が基準値（例えば、９０％）以上かどうかを判断し、カバー率が基準値以上の場合（Ｓ１０７＝Ｙｅｓ）、Ｓ１０８に進む。一方で、基準値を満たさない場合（Ｓ１０７＝Ｎｏ）はカバー率が低いと判断して、Ｓ１０４に進む。Ｓ１０４では、再度、カバー率記憶部１２２に記憶された情報から、効果ａが見込める他の成分を探索する（Ｓ１０４）。効果ａが見込める他の成分として成分Ｃが該当した場合、成分Ｃの腸内環境パターンＺを取得し、その後Ｓ１０６で腸内環境パターンＸ＋Ｙ＋Ｚのカバー率を算出する。ここで、成分Ｂを用いずに成分Ａと成分Ｃのみを用いる場合には、腸内環境パターンＸ＋Ｚのカバー率を算出する。その後、Ｓ１０７でカバー率が基準値以上であるかを判断し、基準値を満たさない場合には、再度Ｓ１０４に戻って次の成分を探索することができる。この場合、カバー率が基準値以上となり、かつ、組成物が含有する成分の数が最小になるように適宜選択することができる。
Next, it is determined whether the calculated coverage rate is greater than or equal to a reference value (for example, 90%), and if the coverage rate is greater than or equal to the reference value (S107=Yes), the process proceeds to S108. On the other hand, if the reference value is not satisfied (S107=No), it is determined that the coverage rate is low, and the process proceeds to S104. In S104, another component that can be expected to have effect a is searched again from the information stored in the coverage storage unit 122 (S104). If component C is found to be another component that can be expected to have effect a, the intestinal environment pattern Z of component C is acquired, and then in S106 the coverage rate of the intestinal environment pattern X+Y+Z is calculated. Here, when using only component A and component C without using component B, the coverage rate of intestinal environment pattern X+Z is calculated. Thereafter, it is determined in S107 whether the coverage rate is equal to or greater than the reference value, and if the reference value is not satisfied, the process can return to S104 again to search for the next component. In this case, it can be appropriately selected so that the coverage is equal to or higher than the reference value and the number of components contained in the composition is minimized.
情報提供部１１５は、取得情報記憶部１２３に記憶された情報を、例えば、ユーザ端末２に提供する（Ｓ１０８）。必要に応じて、各情報に上記の付加情報を追加してもよい。そして、ユーザ端末２に提供されたデータに基づき、所定の効果ａを有する複数の成分を含有する組成物を製造する（図示せず）。
The information providing unit 115 provides the information stored in the acquired information storage unit 123, for example, to the user terminal 2 (S108). The above additional information may be added to each piece of information as necessary. Then, based on the data provided to the user terminal 2, a composition containing a plurality of components having a predetermined effect a is manufactured (not shown).
以上が、本発明の実施形態に係る情報処理システムおよび情報処理方法の基本的な説明である。本発明によれば、所定の効果（機能性）を有する成分を含有する組成物に対して、その効果を有さない対象者（すなわち、ノンレスポンダー）に対し、その効果をもたらすと考えられる別の成分をデータベースや文献調査等により探索し、この別の成分も含有するものとすることができる。これにより、所定の集団において、所定の効果に対するカバー率が高い組成物を提供することができる。このように、本発明は、新たな設計方法により、所定の集団において、所定の効果に対するカバー率が高い機能性物質を提供するものである。
The above is the basic explanation of the information processing system and information processing method according to the embodiment of the present invention. According to the present invention, a composition containing a component having a predetermined effect (functionality) is considered to have that effect on a subject who does not have that effect (i.e., a non-responder). Another component can be searched for through databases, literature searches, etc., and this other component can also be included. Thereby, it is possible to provide a composition that has a high coverage rate for a predetermined effect in a predetermined population. In this manner, the present invention provides a functional substance that has a high coverage rate for a predetermined effect in a predetermined population using a new design method.
図６に示すように、上述した実施形態では、所定の効果ａを有する成分Ａの選択から開始し、所定のカバー率を満たし、かつ成分の数が最小になるように選択する例を示したが、カバー率を最大化し、かつ成分の数が所定の数以下になるように適宜選択することができる。また、成分の数を限定せずに、カバー率が最大になるように成分を適宜選択することができる。
As shown in FIG. 6, in the embodiment described above, an example is shown in which the selection starts with component A having a predetermined effect a, and the selection is performed such that a predetermined coverage rate is satisfied and the number of components is minimized. However, the number of components can be appropriately selected so as to maximize the coverage and keep the number of components to a predetermined number or less. Furthermore, without limiting the number of components, the components can be appropriately selected so as to maximize the coverage rate.
なお、上述した実施形態において、所定の効果ａを有する成分の全てが組成物に対して適用できる訳ではない。例えば、所定の組成物が「ヨーグルト」であった場合に、所定の効果ａが便通改善効果であり、成分Ａがビフィズス菌ＢＢ５３６、成分ＢがＬＢ８１乳酸菌、成分Ｃがラクリスであることができるが、ここに便通改善効果のための他の成分としてヨーグルトが不味くなるような成分（例えば、成分として「醤油」）を含有しないことが好ましい。
Note that in the embodiments described above, not all components having the predetermined effect a can be applied to the composition. For example, when the predetermined composition is "yogurt", the predetermined effect a is a bowel movement improving effect, component A can be Bifidobacterium BB536, component B can be LB81 lactic acid bacteria, and component C can be Lacris. It is preferable that the yogurt does not contain any other ingredients that would make the yogurt taste unpleasant (for example, "soy sauce" as an ingredient) for the purpose of improving bowel movements.
また、上述した実施形態において、組成物は、それぞれの成分の効果を妨げるような成分を含有しないことが好ましい。例えば、所定の組成物が「ヨーグルト」であった場合に、乳酸菌の働きを阻害したり、菌材であれば互いに競合たり、正反対の効果を有する成分だったり、混ぜたら明らかに不味くなるような成分は好ましくない。
Furthermore, in the embodiments described above, it is preferable that the composition does not contain any components that would interfere with the effects of each component. For example, if a given composition is ``yoghurt,'' the ingredients may inhibit the action of lactic acid bacteria, or if they are bacterial ingredients, they may compete with each other or have opposite effects, or if they are mixed together, they will obviously taste bad. The ingredients are unfavorable.
上記の成分に関する情報は、例えば、カバー率記憶部１２２や付加情報記憶部１２４に記憶させることができ、また、他の記憶部に記憶させることができる。サーバ１がこのような情報を有することによって、成分を選択するときの精度を向上させることができる。
The information regarding the above components can be stored in, for example, the coverage storage section 122 or the additional information storage section 124, or can be stored in another storage section. By having the server 1 with such information, accuracy when selecting components can be improved.
以上、本実施形態について説明したが、上記実施形態は本発明の理解を容易にするためのものであり、本発明を限定して解釈するためのものではない。本発明は、その趣旨を逸脱することなく、変更、改良され得ると共に、本発明にはその等価物も含まれる。
Although the present embodiment has been described above, the above embodiment is for facilitating the understanding of the present invention, and is not intended to be interpreted as limiting the present invention. The present invention may be modified and improved without departing from the spirit thereof, and the present invention also includes equivalents thereof.
１ サーバ
２ ユーザ端末
３ ネットワーク 1 Server 2 User terminal 3 Network
２ ユーザ端末
３ ネットワーク 1 Server 2 User terminal 3 Network
Claims (14)
- 所定の効果を有する２つ以上の成分を含有する組成物であって、
前記各成分が、所定の集団において、前記効果が期待できる対象者の割合を示すカバー率の合計が所定の割合以上になるように選択された、組成物。 A composition containing two or more components having a predetermined effect,
A composition in which each of the components is selected such that the total coverage rate, which indicates the proportion of subjects for whom the effect can be expected in a predetermined group, is equal to or higher than a predetermined proportion. - 所定の効果を有する２つ以上の成分を含有する組成物であって、
前記成分が、所定の集団において、前記各成分について設定された前記効果が期待できる腸内環境パターンの対象者の割合を示すカバー率の合計が所定の割合以上になるように選択された、組成物。 A composition containing two or more components having a predetermined effect,
A composition in which the ingredients are selected such that the total coverage rate indicating the proportion of subjects with the intestinal environment pattern in which the effect set for each ingredient can be expected in a predetermined population is equal to or higher than a predetermined proportion. thing. - 第１の効果が見込める第１の成分および第２の成分を含有し、
前記第１の成分は、前記第１の効果が見込める第１の腸内環境パターンのカバー率Ｘを有し、
前記第２の成分は、前記第１の効果が見込める第２の腸内環境パターンのカバー率Ｙを有し、
前記第１および第２の腸内環境パターンのカバー率の合計が所定の割合以上である、組成物。 Contains a first component and a second component that are expected to have the first effect,
The first component has a coverage rate X of a first intestinal environment pattern in which the first effect can be expected,
The second component has a coverage rate Y of a second intestinal environment pattern in which the first effect can be expected,
A composition in which the total coverage of the first and second intestinal environment patterns is equal to or higher than a predetermined ratio. - 第１の成分において、第１の効果が見込める第１の腸内環境パターンを取得するステップと、
前記第１の腸内環境パターンのカバー率を算出するステップと、
前記カバー率が基準値以上であるかを判断するするステップと、
第２の腸内環境パターンに前記第１の効果が見込める第２の成分を探索するステップと、
前記第２の成分において、前記第２の腸内環境パターンを取得するステップと、
前記第１および第２の腸内環境パターンのカバー率を算出するステップと、
前記第１および第２の成分を含有する組成物を製造するステップと、
により得られた、組成物。 obtaining a first intestinal environment pattern in which the first effect can be expected for the first ingredient;
calculating the coverage rate of the first intestinal environment pattern;
determining whether the coverage rate is equal to or higher than a reference value;
searching for a second component that is expected to have the first effect on a second intestinal environment pattern;
In the second component, acquiring the second intestinal environment pattern;
calculating the coverage of the first and second intestinal environment patterns;
producing a composition containing the first and second components;
A composition obtained by. - 所定の効果を有する２つ以上の成分を含有する、組成物における成分の選択方法であって、
前記各成分が、所定の集団において、前記効果が期待できる対象者の割合を示すカバー率の合計が所定の割合以上になるように選択された、選択方法。 A method for selecting components in a composition containing two or more components having a predetermined effect, the method comprising:
A selection method in which each of the components is selected such that a total coverage rate indicating the proportion of subjects for whom the effect can be expected in a predetermined group is equal to or higher than a predetermined proportion. - 所定の効果を有する２つ以上の成分を含有する、組成物における成分の選択方法であって、
前記成分が、所定の集団において、前記各成分について設定された前記効果が期待できる腸内環境パターンの対象者の割合を示すカバー率の合計が所定の割合以上になるように選択された、選択方法。 A method for selecting components in a composition containing two or more components having a predetermined effect, the method comprising:
The ingredients are selected such that the total coverage rate indicating the proportion of subjects with the intestinal environment pattern in which the effect set for each ingredient can be expected in a predetermined population is equal to or higher than a predetermined proportion. Method. - 第１の効果が見込める第１の成分および第２の成分を含有し、
前記第１の成分は、前記第１の効果が見込める第１の腸内環境パターンのカバー率Ｘを有し、
前記第２の成分は、前記第１の効果が見込める第２の腸内環境パターンのカバー率Ｙを有し、
前記第１および第２の腸内環境パターンのカバー率の合計が所定の割合以上である、組成物における成分の選択方法。 Contains a first component and a second component that are expected to have the first effect,
The first component has a coverage rate X of a first intestinal environment pattern in which the first effect can be expected,
The second component has a coverage rate Y of a second intestinal environment pattern in which the first effect can be expected,
A method for selecting components in a composition, wherein the total coverage of the first and second intestinal environment patterns is a predetermined ratio or more. - 第１の成分において、第１の効果が見込める第１の腸内環境パターンを取得するステップと、
前記第１の腸内環境パターンのカバー率を算出するステップと、
前記カバー率が基準値以上であるかを判断するするステップと、
第２の腸内環境パターンに前記第１の効果が見込める第２の成分を探索するステップと、
前記第２の成分において、前記第２の腸内環境パターンを取得するステップと、
前記第１および第２の腸内環境パターンのカバー率を算出するステップと、
前記第１および第２の成分を含有する組成物を製造するステップと、
により得られた、組成物における成分の選択方法。 obtaining a first intestinal environment pattern in which the first effect can be expected for the first ingredient;
calculating the coverage rate of the first intestinal environment pattern;
determining whether the coverage rate is equal to or higher than a reference value;
searching for a second component that is expected to have the first effect on a second intestinal environment pattern;
In the second component, acquiring the second intestinal environment pattern;
calculating the coverage of the first and second intestinal environment patterns;
producing a composition containing the first and second components;
A method for selecting components in a composition obtained by - 所定の効果を有する２つ以上の成分を含有する、組成物の製造方法であって、
前記各成分が、所定の集団において、前記効果が期待できる対象者の割合を示すカバー率の合計が所定の割合以上になるように選択された、組成物の製造方法。 A method for producing a composition containing two or more components having a predetermined effect, the method comprising:
A method for producing a composition, wherein each of the components is selected such that the total coverage rate, which indicates the proportion of subjects for whom the effect can be expected in a predetermined group, is equal to or higher than a predetermined proportion. - 所定の効果を有する２つ以上の成分を含有する、組成物の製造方法であって、
前記成分が、所定の集団において、前記各成分について設定された前記効果が期待できる腸内環境パターンの対象者の割合を示すカバー率の合計が所定の割合以上になるように選択された、組成物の製造方法。 A method for producing a composition containing two or more components having a predetermined effect, the method comprising:
A composition in which the ingredients are selected such that the total coverage rate indicating the proportion of subjects with the intestinal environment pattern in which the effect set for each ingredient can be expected in a predetermined population is equal to or higher than a predetermined proportion. How things are manufactured. - 第１の効果が見込める第１の成分および第２の成分を含有し、
前記第１の成分は、前記第１の効果が見込める第１の腸内環境パターンのカバー率Ｘを有し、
前記第２の成分は、前記第１の効果が見込める第２の腸内環境パターンのカバー率Ｙを有し、
前記第１および第２の腸内環境パターンのカバー率の合計が所定の割合以上である、組成物の製造方法。 Contains a first component and a second component that are expected to have the first effect,
The first component has a coverage rate X of a first intestinal environment pattern in which the first effect can be expected,
The second component has a coverage rate Y of a second intestinal environment pattern in which the first effect can be expected,
A method for producing a composition, wherein the total coverage of the first and second intestinal environment patterns is equal to or higher than a predetermined ratio. - 第１の成分において、第１の効果が見込める第１の腸内環境パターンを取得するステップと、
前記第１の腸内環境パターンのカバー率を算出するステップと、
前記カバー率が基準値以上であるかを判断するするステップと、
第２の腸内環境パターンに前記第１の効果が見込める第２の成分を探索するステップと、
前記第２の成分において、前記第２の腸内環境パターンを取得するステップと、
前記第１および第２の腸内環境パターンのカバー率を算出するステップと、
前記第１および第２の成分を含有する組成物を製造するステップと、
により得られた、組成物の製造方法。 obtaining a first intestinal environment pattern in which the first effect can be expected for the first ingredient;
calculating the coverage rate of the first intestinal environment pattern;
determining whether the coverage rate is equal to or higher than a reference value;
searching for a second component that is expected to have the first effect on a second intestinal environment pattern;
In the second component, acquiring the second intestinal environment pattern;
calculating the coverage of the first and second intestinal environment patterns;
producing a composition containing the first and second components;
A method for producing a composition obtained by - 第１の成分において、第１の効果が見込める第１の腸内環境パターンを取得する取得部と、
前記第１の腸内環境パターンのカバー率を算出する算出部と、
前記カバー率が基準値以上であるかを判断するする判断部と、
第２の腸内環境パターンに前記第１の効果が見込める第２の成分を探索する探索部と、
取得された情報を提供する情報提供部と、を備え、
前記取得部は、前記第２の成分において、前記第２の腸内環境パターンを取得し、
前記算出部は、前記第１および第２の腸内環境パターンのカバー率を算出する、情報処理システム。 an acquisition unit that acquires a first intestinal environment pattern in which a first effect can be expected for the first component;
a calculation unit that calculates the coverage rate of the first intestinal environment pattern;
a determination unit that determines whether the coverage rate is equal to or higher than a reference value;
a search unit that searches for a second component that is expected to have the first effect on a second intestinal environment pattern;
an information provision unit that provides the acquired information;
The acquisition unit acquires the second intestinal environment pattern in the second component,
The information processing system, wherein the calculation unit calculates coverage rates of the first and second intestinal environment patterns. - 第１の成分において、第１の効果が見込める第１の腸内環境パターンを取得するステップと、
前記第１の腸内環境パターンのカバー率を算出するステップと、
前記カバー率が基準値以上であるかを判断するするステップと、
第２の腸内環境パターンに前記第１の効果が見込める第２の成分を探索するステップと、
前記第２の成分において、前記第２の腸内環境パターンを取得するステップと、
前記第１および第２の腸内環境パターンのカバー率を算出するステップと、
取得された情報を提供するステップと、
を有する、コンピュータによる情報処理方法。 obtaining a first intestinal environment pattern in which the first effect can be expected for the first ingredient;
calculating the coverage rate of the first intestinal environment pattern;
determining whether the coverage rate is equal to or higher than a reference value;
searching for a second component that is expected to have the first effect on a second intestinal environment pattern;
In the second component, acquiring the second intestinal environment pattern;
calculating the coverage of the first and second intestinal environment patterns;
providing the obtained information;
An information processing method using a computer.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/JP2022/026659 WO2024009373A1 (en) | 2022-07-05 | 2022-07-05 | Composition, method for selecting components in composition, method for producing composition, information processing system, and information processing method |
| JP2023501580A JP7336168B1 (en) | 2022-07-05 | 2022-07-05 | COMPOSITION, METHOD FOR SELECTING COMPONENTS IN COMPOSITION, METHOD FOR MANUFACTURING COMPOSITION, INFORMATION PROCESSING SYSTEM AND INFORMATION PROCESSING METHOD |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/JP2022/026659 WO2024009373A1 (en) | 2022-07-05 | 2022-07-05 | Composition, method for selecting components in composition, method for producing composition, information processing system, and information processing method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2024009373A1 true WO2024009373A1 (en) | 2024-01-11 |
Family
ID=87764088
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2022/026659 WO2024009373A1 (en) | 2022-07-05 | 2022-07-05 | Composition, method for selecting components in composition, method for producing composition, information processing system, and information processing method |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JP7336168B1 (en) |
| WO (1) | WO2024009373A1 (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016204355A (en) * | 2014-09-10 | 2016-12-08 | 日環科学株式会社 | Probiotics or prebiotics, as well as production methods, microorganism preparations, health foods, and medicines thereof |
| JP2018049645A (en) * | 2015-08-12 | 2018-03-29 | ヤヱガキ醗酵技研株式会社 | Information processing device, information processing method, and program |
-
2022
- 2022-07-05 JP JP2023501580A patent/JP7336168B1/en active Active
- 2022-07-05 WO PCT/JP2022/026659 patent/WO2024009373A1/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016204355A (en) * | 2014-09-10 | 2016-12-08 | 日環科学株式会社 | Probiotics or prebiotics, as well as production methods, microorganism preparations, health foods, and medicines thereof |
| JP2018049645A (en) * | 2015-08-12 | 2018-03-29 | ヤヱガキ醗酵技研株式会社 | Information processing device, information processing method, and program |
Non-Patent Citations (3)
| Title |
|---|
| ANONYMOUS: "How would you classify people around the world based on their intestinal bacteria types? | Interesting stories about the intestines Part 1 ", SUNSTAR HEALTH DOJO, 28 October 2020 (2020-10-28), pages 1 - 4, XP093124672, Retrieved from the Internet <URL:https://www.kenkodojo.com/guts/detail1/> * |
| ANONYMOUS: "MG Diet Support (for companies) <br> ~ Utilize AI! Weight loss support program that takes into account intestinal environment type", METAGEN CO., LTD., 2 September 2022 (2022-09-02), XP093124666, Retrieved from the Internet <URL:https://metagen.co.jp/service/biz-dev/mgdietsupport/> [retrieved on 20240129] * |
| ANONYMOUS: "What are the characteristics of Japanese intestinal bacteria? Why are they different from those in the United States and China?", ASAHI SHIMBUN COMPANY, 28 April 2021 (2021-04-28), XP093124674, Retrieved from the Internet <URL:https://www.asahi.com/relife/article/14339144> [retrieved on 20240129] * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP7336168B1 (en) | 2023-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zickgraf et al. | Initial validation of the Nine Item Avoidant/Restrictive Food Intake disorder screen (NIAS): A measure of three restrictive eating patterns | |
| Eaton et al. | Effectiveness of provision of animal‐source foods for supporting optimal growth and development in children 6 to 59 months of age | |
| Tuddenham et al. | The intestinal microbiome and health | |
| Laursen et al. | Infant gut microbiota development is driven by transition to family foods independent of maternal obesity | |
| Golley et al. | Motivations for avoiding wheat consumption in Australia: results from a population survey | |
| De Filippo et al. | Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa | |
| Hascoët et al. | Effect of formula composition on the development of infant gut microbiota | |
| Shikany et al. | Association of dietary patterns with the gut microbiota in older, community-dwelling men | |
| Lockyer et al. | Prebiotics–an added benefit of some fibre types | |
| Savy et al. | Are dietary diversity scores related to the socio-economic and anthropometric status of women living in an urban area in Burkina Faso? | |
| Kontogianni et al. | A high polyphenol diet improves psychological well-being: The polyphenol intervention trial (pphit) | |
| Ramin et al. | A prospective analysis of dietary fiber intake and mental health quality of life in the Iowa Women’s Health Study | |
| Berding et al. | Dietary patterns impact temporal dynamics of fecal microbiota composition in children with autism spectrum disorder | |
| Fiese et al. | The Strong Kids 2 birth cohort study: A cell-to-society approach to dietary habits and weight trajectories across the first 5 years of life | |
| Mari-Bauset et al. | Anthropometric measurements and nutritional assessment in autism spectrum disorders: A systematic review | |
| Lee et al. | Relationship between dietary intakes and the double burden of malnutrition in adults of Malang, Indonesia: An exploratory study | |
| Zulkifli et al. | Relationships Between Sensory Processing Disorders With Feeding Behavior Problems Among Children With Autism Spectrum Disorder. | |
| Silvi et al. | Probiotic-enriched foods and dietary supplement containing SYNBIO positively affects bowel habits in healthy adults: an assessment using standard statistical analysis and Support Vector Machines | |
| Hajizadeh et al. | Dietary habits and personal care product use as predictors of urinary concentrations of parabens in Iranian adolescents | |
| Costantini et al. | Effect of die configuration on the physico-chemical properties, anti-nutritional compounds, and sensory features of legume-based extruded snacks | |
| Matsuoka et al. | Relationships between barley consumption and gut microbiome characteristics in a healthy Japanese population: a cross-sectional study | |
| Loncar et al. | Associations of parenting factors and weight related outcomes in African American adolescents with overweight and obesity | |
| Łopusiewicz et al. | Effect of Flaxseed Oil Cake Extract on the Microbial Quality, Texture and Shelf Life of Gluten-Free Bread | |
| Lunken et al. | Variability in gut microbiota response to an inulin-type fructan prebiotic within an in vitro three-stage continuous colonic model system | |
| Aguiar et al. | A Decade of Evidence of Sorghum Potential in the Development of Novel Food Products: Insights from a Bibliometric Analysis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22950167 Country of ref document: EP Kind code of ref document: A1 |